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1. Introduction 
 
1.1 Important physiological nucleotides in human 
 
Nucleotides fulfill a wide range of tasks in physiological processes of the human organism. They 
are the monomeric subunits of the nucleic acid polymers deoxyribonucleic acid (DNA) and ribonucleic 
acid (RNA) (Berg et al., 2002). Furthermore, in biology in general ATP (adenosine 5’-triphosphate) plays 
a fundamental role as a main storage of chemical energy. Importantly, several types of nucleotides serve 
as intracellular or extracellular regulatory or signaling molecules. 
Nucleotides contain purine (adenine, A; guanine, G) or pyrimidine (cytosine, C; uracil, U; 
thymine, T) nucleobase moieties (Figure 1). This nucleobase is bound to a pentose sugar (ribose or 
2-deoxyribose) via a N-glycosidic linkage, thus forming a glycosylamine or a so called nucleoside. The 
nitrogen (N) at position 9 of a purine base and the N at position 1 of a pyrimidine base, respectively, are 
connected to the carbon (C) at position 1’ of the pentose. A phosphate moiety (α-phosphate) is usually 
connected to the C5’ of the sugar via an ester bond, forming a nucleotide or a nucleoside 
monophosphate. Additional phosphates (β, γ, ...) are bound to the α-phosphate via acid anhydride bonds. 
 
 
Figure 1: Structures and nomenclature of the purine nucleotide adenosine 5’-triphosphate (ATP) 
and the pyrimidine nucleotide uridine 5’-triphosphate (UTP). 
 
Important naturally occurring nucleotides other than ATP are ADP (adenosine 5’-diphosphate), 
UTP (uridine 5’-triphosphate), UDP (uridine 5’-diphosphate), and UDP-sugars like UDP-glucose 
(Jacobson et al., 2009). Also, several di-nucleotides with an interconnecting C5’-C5’’ phosphate chain of 
varying length (n = 2-7) have been characterized: ApnA (diadenosine polyphosphates; Guzmán-Aranguez 
et al., 2007; Carracedo et al., 2013), Ap4U (adenosine 5’-tetraphosphate 5’’-uridine; Jankowski et al., 
2005) and the well-known elements of many redox reactions in cells NAD (nicotinamide adenine 
dinucleotide), its C2’ phosphorylated form NADP, and FAD (flavin adenine dinucleotide) (Guzmán-
Aranguez et al., 2007). 
The cyclic nucleotides cAMP (3’-5’-cyclic adenosine monophosphate) and cGMP (3’-5’-cyclic 
guanosine monophosphate) are well established second messengers (Sassone-Corsi, 2012; Hoffmann, 
2005). They are synthesized by adenylyl cyclase (AC) and guanylyl cyclase (GC), respectively, by 
esterification of the 5’ phosphate with the C3’ of the ribose. cCMP (3’-5’-cyclic cytosine monophosphate) 
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and cUMP (3’-5’-cyclic uridine monophosphate) have also been indentified, but their specific roles are 
less well understood (Wolters et al., 2011). 
1.2 The human P1 and P2 nucleotide receptors 
 
The human P1 adenosine receptor family. 
A range of nucleotide and nucleoside receptors, classified as P1 and P2 receptors, are used by 
cells to sense nucleotides and their metabolites. The P1 receptor family includes the four metabotropic (G 
protein-coupled) seven-transmembrane receptors (7TMR) A1, A2A, A2B, and A3 (Fredholm et al., 2001 and 
2011). All P1 receptors can be activated by adenosine, which either is a product of the extracellular 
hydrolysis of adenine nucleotides or is released by cells directly (King et al., 2006). A1 and A3 receptors 
are coupled to Gi signaling, which results in the inhibition of ACs. Conversely, the A2A and A2B receptors 
are coupled to the Gs pathway and induce AC activation. However, coupling of P1 receptors to other G 
proteins has also been reported.  
The human P2 nucleotide receptor family. 
The group of P2 receptors includes the P2X and P2Y receptor families. The P2X1-7 receptors are 
cation channels activated by ATP. The family of P2Y receptors in human consists of eight proteins, the 
P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11-14 receptors. Those are mainly coupled to the Gi, Gs, and/or Gq 
signaling pathways and show overlapping activation patterns by adenine and uridine nucleotides 
(Abbrachio et al., 2006). P2Y receptors are heptahelical transmembrane receptors coupled to intracellular 
G protein signaling. They are assigned to the δ-subfamily of the rhodopsin-related (Class A) G protein-
coupled receptors (GPCRs; Ralevic et al., 1998; Latek et al., 2012). The seven transmembrane helices 
are interconnected by 3 extracellular loops (EL) and 3 cytoplasmic loops (Palczewski et al., 2000). The 
EL and TM regions constitute the nucleotide ligand binding pocket, which faces towards the extracellular 
space. The N-terminus of the receptor protein is located at the extracellular side of the protein, while the 
C-terminus is exposed to the cytoplasm. 
The group of the eight purinergic human P2Y receptors can be divided into either adenine or 
uridine nucleotide-preferring receptors (Abbrachio et al., 2006). While the P2Y1, P2Y11, P2Y12, and P2Y13 
receptors belong to the adenine nucleotide-preferring group, the P2Y4, P2Y6, and P2Y14 receptors can be 
activated by uridine nucleotides. The human P2Y2 receptor equally accepts ATP and UTP. However, 
there are differences regarding the preference for nucleoside di- or triphosphates. At the P2Y1 receptor, 
ADP shows greater potency than ATP. On the other hand, the P2Y11 receptor prefers ATP over ADP. 
Both the P2Y2 and P2Y4 receptors are UTP-preferring receptors, while the P2Y6 receptor is selective for 
UDP. The P2Y12 and P2Y13 receptors are selective for ADP, and the P2Y14 receptor can be activated by 
UDP and UDP-glucose (Chambers et al., 2000; Carter et al., 2009). 
P2Y receptor-mediated intracellular signaling. 
The classification of P2Y receptors based on ligand preferences offers a convenient way to 
discriminate individual receptors. However, this does not reflect the phylogenetic relationship of two 
distinct phylogenetic branches (Constanzi et al., 2004). The P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11 
receptors represent one branch, activating the Gq/G11 signaling pathway. The P2Y12, P2Y13, and P2Y14 
receptors in the second phylogenetic branch are coupled to the Gi pathway. The P2Y2 and P2Y4 receptors 
were found to be additionally linked to Gi signaling (Murthy et al., 1998; Communi et al., 1996). 
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The activation of the Gq pathway leads to activation of phospholipase C (PLC) and consequently 
to the production of the soluble inositol 1,4,5-trisphosphate (IP3). This eventually triggers the elevation of 
the intracellular Ca2+ concentration ([Ca2+]i) via Ca2+ release from intracellular stores. At the same time, 
the membrane-bound second messenger diacylglycerol is generated and activates protein kinase C 
(PKC).  
The activation of the Gi signaling pathway leads to the inhibition of AC, thus the inhibition of 
cAMP synthesis. The P2Y11 receptor is the only P2Y receptor, which triggers the Gs signal transduction 
pathway and therefore the activation of AC. cAMP subsequently activates the cAMP-dependent protein 
kinases (protein kinase A; PKA) which in turn can phosphorylate a wide range of target proteins. Another 
way of P2Y receptor signaling works via β-arrestin recruitment following the phosphorylation of the 
receptor by G protein-coupled receptor kinases (GRKs). These steps mediate the nucleotide-induced 
P2Y receptor internalization (Hoffman et al., 2008b). Additionally, β-arrestin recruitment can facilitate 
signaling via mitogen-activated protein kinases (MAPK) and other intracellular pathways (Ferguson 2001; 
Lefkowitz et al., 2005). The translocation of β-arrestin1 or β-arrestin2 to the plasma membrane upon P2Y 
receptor activation defines whether a rapid receptor recycling to the cell surface takes place, or the 
receptor is recycled only slowly, or even degraded inside the endosomes.  
P2Y receptors are major drug targets. 
Because P2Y receptors are widely expressed and contribute to the important purinergic signaling 
(chapter 1.5) in all human tissues, these receptors are considered to be major drug targets. For this 
reason, many different nucleotide and non-nucleotide compounds have been investigated in functional 
assays in order to determine their agonist or antagonist potential. The development of potent agonists 
and antagonists, which are highly resistant to hydrolysis, is mandatory for drug development. 
Furthermore, the selectivity of synthetic ligands for a certain P2Y receptor is needed for the investigation 
of physiological P2Y receptor functions, since several of the P2Y receptors can be activated by adenine 
and uridine nucleotide derivatives. 
Concentration-response experiments are a common way to evaluate whether a receptor ligand 
has the ability to activate a specific receptor-mediated downstream signaling pathway. This method 
involves the application of a range of concentrations of the ligand to cells expressing the P2Y receptor of 
interest. The determination of the amplitudes of the concentration-dependent downstream responses 
allows for the calculation of the EC50 value. The latter gives the concentration of the ligand at which a 
half-maximal downstream response is achieved. The EC50 value helps to assess the so-called ligand 
efficacy which describes the consequences of the ligand binding to the receptor and the downstream 
signaling pathways (Strange, 2008). The EC50 value also is referred to as the ‘potency of a ligand’. A low 
EC50 value represents a high potency to induce a specific downstream signaling pathway. Determination 
of the EC50 value of an agonist can also be used to evaluate how receptor mutations affect the receptor 
signaling or activation. Importantly, the EC50 value of a ligand at a certain receptor depends on the 
investigated downstream signaling pathway, since different downstream signaling components are 
involved. Moreover, the efficacy of a ligand should not be mistaken for its affinity, which only describes 
the dissociation constant of the ligand bound to the receptor (Strange, 2008). The receptor affinity to a 
ligand can dramatically change as a consequence of the ligand binding and of G protein-coupling to 
1. Introduction 
 
4 
GPCRs. Thus, the EC50 value of a GPCR is a functional parameter of the ternary complex of ligand-
receptor-G protein.  
In the present study, concentration-response experiments were performed in order to assess the 
potency of novel P2Y11 and P2Y6 receptor agonists featuring several molecular substitutions. Additionally, 
the functional consequences of an amino acid shift in the P2Y11 receptor protein on the efficacy of several 
nucleotides was investigated this way.  
1.3 The human P2Y11 receptor 
  
The human P2Y11 receptor was first characterized by Communi and coworkers in 1997. The gene 
was found to be the only P2Y receptor gene containing an intron which separates the first 18 codons from 
the rest of the coding sequence. The P2RY11 gene is located on chromosome 19p31 upstream of the 
human ortholog of the yeast SSF1 gene. In human, SSF1 mRNA can be detected in many tissues 
(Suarez-Huerta et al., 2000). Intergenic splicing was reported to lead to the formation of a SSF1-P2Y11 
receptor fusion protein. The first three codons which were initially reported for the P2RY11 gene in fact 
were coming from the SSF1 part of the SSF1-P2Y11 fusion cDNA (Communi et al., 2001). 
The presence of P2RY11 mRNA was detected in virtually all human tissues. It is most abundant 
in brain, pituitary, lymphocytes, and spleen. It was also found at significant levels in macrophages, 
dendritic cells (DC), neutrophils, platelets, and mast cells (Berchtold et al., 1999; Moore et al., 2001; 
Schnurr et al., 2003; Feng et al., 2004). However, Wang et al. (2003) found no P2RY11 mRNA in human 
platelets. In the human heart, the P2RY11 mRNA was found to some extent as well (Wihlborg et al., 
2006). 
The P2Y11 receptor has been reported to interact with the P2Y1 receptor (Ecke et al., 2008a). This 
interaction results in distinct changes of pharmacological and functional properties of the receptors. The 
P2Y11 receptor, for instance, is not able to undergo nucleotide-induced internalization unless the P2Y1 
receptor is co-expressed. The latter receptor undergoes nucleotide-induced, clathrin-dependent 
internalization on its own (Mundell et al., 2006). In HEK293 cells, which endogenously express the P2Y1 
receptor, the potent P2Y1 receptor agonist 2-MeS-ADP (2-methlythio-adenosine 5’-diphosphate) induces 
strong internalization of the P2Y11 receptor. Importantly, the P2Y11 receptor-specific antagonist NF157 
was unable to block the internalization of the P2Y11 receptor in HEK293 cells. Only the P2Y1 receptor-
specific antagonist MRS2179 (N6-methyl-2’-deoxyadenosine 3’,5’-diphosphate) was able to completely 
inhibit nucleotide-induced P2Y11 receptor internalization. The formation of P2Y1-P2Y11 receptor oligomers 
explains why a P2Y1 but not a P2Y11 receptor-specific antagonist was able to inhibit the internalization of 
the P2Y11 receptor.  
Structure-activity relationships of agonists and antagonists of the human P2Y11 receptor. 
The quest for potent, selective, and stable agonists and antagonists lead to significant findings 
about the P2Y11 receptor structure including the nucleotide binding pocket and structure-activity 
relationships of ligands (Jacobson et al., 2012). Within the P2Y receptor family, the P2Y1 and P2Y11 
receptors are the closest homologues with 38% sequence identity and 72% similarity of the TM domains 
(Zylberg et al., 2007). This results in 33% overall amino acid identity (Communi et al., 1999). The P2Y11 
receptor has the largest EL2 and EL3 regions within the human P2Y receptor family. Due to their 
flexibility, the spatial organization of the extracellular loops can hardly be modeled. However, for the P2Y1 
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receptor the EL2 and EL3 were reported to contribute to ligand binding and recognition (Moro et al., 1999; 
Hoffmann et al., 1999). This could indicate that the EL2 and EL3 of the P2Y11 receptor contribute to the 
distinct activation pattern of the receptor, when compared to other P2Y receptors. Zylberg et al. (2007) 
presented a computational model of the TM regions of the P2Y11 receptor which was verified by 
mutational analysis. In this study, the secondary structure of the P2Y11 receptor was derived from a P2Y1 
receptor homology model published by Major et al. (2004a). The P2Y1 receptor structure itself is based 
on the crystal structure of bovine rhodopsin (Okada et al., 2002), the first crystallized GPCR (Palczewski 
et al., 2000). The so-called homology modeling is a valuable method for the deduction of protein 
structures from the crystal structure of a closely related protein. The receptor model can be used for the 
investigation of the parameters of ligand-receptor binding. Thus, it is an important tool for computational 
fitting analysis of hypothetical ligand structures interacting with the receptor binding pocket. 
With the help of the P2Y11 receptor model, residues Arg106, Phe109, Ser206, Arg268, Arg307, 
and Met310 were identified to be directly involved in nucleotide binding. Furthermore, the nucleotide 
binding pocket of the P2Y11 receptor was found to be very similar to that of the P2Y1 receptor.  
The model further revealed a hydrophobic pocket within the receptor. The carbon atom C2 of the 
nucleobase of an adenine nucleotide (Figure 1) bound to the receptor would be located near this 
hydrophobic pocket. This consequently led to the hypothesis that substitutions at the C2 position of 
nucleotides could possibly improve nucleotide potency at the P2Y11 receptor. Experimental results show 
that 2-Cl-ATP (2-chloro-adenosine 5’-triphosphate) and 2-MeS-ATP (2-methlythio-adenosine 
5’-triphosphate), with rather small C2 substitutions, are poor agonists of the P2Y11 receptor. However, 
AR-C67085 (2-propylthio-ATP-β,γ-dichloromethylene), which carries a larger 2-propylthio substitution at 
position C2, is a very potent agonist. 
The following rank order of nucleotide potencies for the [Ca2+]i elevation was reported by 
Communi et al. (1999): AR-C67085 > BzATP (2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-triphosphate) > 
ATP-γS (adenosine 5’-triphosphate-γ-thio) > dATP (2'-deoxyadenosine 5'-triphosphate) > ATP > ATP-βS 
(adenosine 5’-triphosphate-β-thio) > 2-MeS-ATP. The same rank order applies for the nucleotide-induced 
accumulation of cAMP with the only difference that ATP-γS was slightly more potent than BzATP. Meis et 
al. (2010) reported that the non-nucleotide compound NF546, a suramin derivative, is a specific agonist of 
the P2Y11 receptor. Interestingly, suramin, a symmetrical, polysulfonated derivative of urea containing 
eight benzene rings, is an unspecific antagonist for P2 receptors. It was also used as basis for the 
development of the specific P2Y11 receptor antagonist NF157 (Ullmann et al., 2005). ADP, AMP 
(adenosine 5'-monophosphate), adenosine, UTP, UDP, GTP (guanosine 5’-triphosphate), CTP (cytidine 
5'-triphosphate), TTP (thymidine 5’-triphosphate), ITP (inosine 5'-triphosphate), as well as the di-
adenosine nucleotides Ap4A, Ap5A, and Ap6A all turned out to be inactive at the human P2Y11 receptor 
(Communi et al., 1997). 
The P2Y11 receptor diastereoselectivity is opposite to that of the P2Y1 receptor (Ecke et al., 
2006). For this study, a new chiral center was added to several nucleotides by substituting a non-bridging 
oxygen of the α-phosphate with a borano or thio group. The P2Y11 receptor clearly preferred the Sp-
isomers of ATP-αB (adenosine 5’-triphosphate-α-borano), 2-MeS-ATP-αB (2-methylthio-adenosine 
5’-triphosphate-α-borano), and 2-Cl-ATP-αB (2-chloro-adenosine 5’-triphosphate-α-borano) over the 
respective Rp-isomers. In contrast, the P2Y1 receptor preferred the Rp-isomers of these nucleotides. 
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Additionally, it was found that Pα-substitutions in most cases helped to improve nucleotide potencies at 
both receptors, with the preferred isomers showing the greatest improvements. At the P2Y11 receptor, the 
EC50 value for ATP-αB (Sp) was 0.34 µM compared to 2.83 µM for ATP. 2-MeS-ATP-αB (Sp) had an 
EC50 value of 0.26 µM compared to 13.8 µM for 2-MeS-ATP. 2-Cl-ATP-αB (Sp) showed an EC50 of 
0.47 µM, while the parent compound 2-Cl-ATP was a very weak agonist of the P2Y11 receptor with an 
EC50 value higher than 30 µM. The residue responsible for the stereospecific recognition of nucleotides is 
Arg268 located in TM6. This arginine is part of the group of amino acids, which compose the binding 
pocket, and it interacts with the triphosphate chain of bound nucleotides (Ecke et al., 2008b). The 
mutation of Glu186, located in EL2 and not directly involved in nucleotide binding, further increased the 
degree of stereospecificity. 
The human P2Y11 receptor has a strong connection to immune cell functions.  
The P2Y11 receptor mediates the maturation of DCs after stimulation with extracellular ATP 
(Wilkin et al., 2001). The migration of DCs (Schnurr et al., 2003), the release of Interleukin (IL)-8 (Meis et 
al., 2010) and IL-12, as well as stimulation of IL-10 production (Wilkin et al., 2002) are also regulated by 
the P2Y11 receptor. Another connection of the P2Y11 receptor to immune system responses was found 
with the ATP-induced inhibition of the constitutive apoptosis of neutrophils, which is important for the 
balance between the perpetuation of inflammation and its down-regulation after successful clearance of 
the pathogens (Vaughan et al., 2007). ATP released by endothelial cells can inhibit chemotaxis and 
cytotoxicity of natural killer cells via activation of the P2Y11 receptor (Gorini et al., 2010). This receptor 
also regulates the lipopolysaccharid-induced activation of THP-1 cells via autocrine ATP signaling and 
release of IL-6 (Sakaki et al., 2013). The expression levels of the P2RY11 mRNA in natural killer cells and 
CD8+ T-lymphocytes are reduced as a consequence of a single-nucleotide polymorphism (SNP) in the 3’-
untranslated region of the P2RY11 gene (rs2305795; Kornum et al., 2011). The P2Y11 receptor-mediated 
protection against ATP-induced cell death is also decreased. This P2Y11 receptor mutation is associated 
with narcolepsy with cataplexy, an auto-immune disease involving the loss of hypocretin-producing 
neurons in the hypothalamus. 
The dataset of the Malmö diet and cancer study revealed that the SNP rs3745601, which is 
located in the coding region of the P2RY11 gene, was present in 22.9% of patients with acute myocardial 
infarction (AMI; Amisten et al., 2007). It was found in only 19.8% of the individuals of the control group. 
The SNP results in the incorporation of a threonine instead of an alanine at position 87 (Ala-87-Thr, 
A87T), near the extracellular end of TM2, of the P2Y11 receptor protein. Early onset AMI of homozygous 
individuals showed the strongest correlation to the SNP. Additionally, individuals with this SNP were 
found to have increased concentrations of C-reactive protein, an acute phase protein and a general 
marker for inflammatory processes. A main cause for AMI is atherosclerosis (Tabas, 2010). Dendritic 
cells, macrophages, and mast cells contribute to the development of atherosclerosis. These cells are 
known for co-expression of the P2Y11 and the P2Y1 receptor. Considering the formation of oligomers of 
the P2Y11 and P2Y1 receptors, the question arises whether the aforementioned resulting alteration of the 
receptor function has a pathological relevance. Thus, the impact of the A87T amino acid shift in the 
human P2Y11 receptor on the activity of cells which co-express both receptors is of special interest. 
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1.4 The human P2Y6 receptor 
 
The human P2Y6 receptor was first described by Communi et al. in 1996. The P2RY6 receptor 
gene is located on chromosome 11q13.5, and the corresponding messenger RNA was detected in the 
spleen, placenta, thymus, small intestine, as well as in neutrophils, lymphocytes, and monocytes (Jin et 
al., 1998). A number of reports addressed pharmacology and physiological roles of the human P2Y6 
receptor. Several studies showed a clear link to immune system-related processes. In monocytes, UDP 
mediates the release of the pro-inflammatory IL-8 (also called CXCL8) via activation of the P2Y6 receptor 
(Warny et al., 2001). IL-8 is a powerful attractant of neutrophils, macrophages, and dendritic cells to a site 
of inflammation. In the same study, the known lipopolysaccharid-induced secretion of IL-8 by THP-1 
monocytes was described to function via the autocrine activation of P2Y6 receptors by nucleotides. The 
UDP-induced release of the pro-inflammatory cytokines IL-8, tumor necrosis factor-α (TNF-α), Interferon 
gamma-induced protein (IP)-10, and monocyte chemotactic protein (MCP)-1 via the P2Y6 receptor 
signaling was later demonstrated for the human promonocytic cell line U937 (Cox et al., 2005). However, 
in 1321N1 astrocytoma cells expressing the P2Y6 receptor a UDP-dependent secretion of TNF-α could 
not be detected. This indicates that cell type-specific, subcellular mechanisms are necessary for the P2Y6 
receptor-mediated release of TNF-α, which seem to be present in monocytic cells, but not in the 1321N1 
cell line.  
The TNF-α-induced secretion of IL-8 was triggered by UDP in an ERK-dependent fashion in 
human ARPE-19 (american retinal pigment epithelium type 19) cells, probably regulated by the P2Y6 
receptor (Relvas et al., 2009). RPE cells form the blood-retinal-barrier. In auto-immune uveitis, these cells 
recruit inflammatory cells into the eye. This may result in permanent loss of vision.  
It was shown that T cells infiltrating sites of intestinal inflammation express the P2Y6 receptor 
(Somers et al., 1998). Furthermore, the P2Y6 receptor is also expressed by the human intestinal epithelial 
cells, which release IL-8 upon receptor activation by UDP (Grbic et al., 2012).  
In human lung epithelial cells, human neutrophil peptide (HNP)-induced production of IL-8 was 
also shown to be dependent on P2Y6 receptor activity (Khine et al., 2006). HNPs are produced and 
released by neutrophils, which play a crucial role in the innate immune system (Mantovani et al., 2011).  
In human mast cell lines, it was demonstrated that the P2Y6 receptor interacts with the cysteinyl 
leukotriene receptor 1 (CysLT1R) to promote chemokine secretion (Jiang et al., 2009). In this study, also 
mouse bone marrow-derived mast cells (mBMMC) were used to demonstrate cytoprotection mediated by 
both receptors together. Cysteinyl leukotrienes are secreted by cells of the innate immune system and 
are potent mediators of immune responses. The CysLT1 receptor is known for its contribution to the 
development of asthma (Camargo et al., 2002). Hence, there are strong indications for an important 
contribution of the P2Y6 receptor to the innate immune response.  
Other reports link the P2Y6 receptor to processes outside the immune system functions. The 
activation of P2Y6 receptors by the potent agonist UTPβS (uridine 5’-triphosphate-β-thio) induced 
contractions of human cerebral arteries. This offers a possible way to treat cerebral vasospasm via P2Y6 
receptor inhibition (Malmsjö et al., 2003). The receptor was further found to be involved in the regulation 
of fluid and electrolyte transport in human bronchial epithelial cell lines (Wong et al., 2008). 
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The rank order of nucleotide potencies at the P2Y6 receptor as reported by Communi et al. in 
1996 is UDP > 5-Br-UTP (5-bromo-uridine 5’-triphosphate) > UTP > ADP > 2-MeS-ATP. Several 
nucleotide derivatives based on the non-selective physiological P2Y6 receptor agonist UDP were 
developed (Jacobson et al., 2009 and 2012). UDP-βS, which carries a thio-substitution of a non-bridging 
oxygen at the β-phosphate, was found to be 6-fold more potent than UDP. Modifications at the uracil ring, 
however, did not result in derivatives that were much more potent in activating the P2Y6 receptor than 
UDP. A modification at position 3 of the uracil ring of UDP made 3-phenylacyl-UDP, which was only 
slightly more potent than its parent compound (El-Tayeb et al., 2006). 5-Br-UDP and 5-I-UDP 
(5-iodo-uridine 5’-triphosphate) were equipotent with UDP (Nicholas et al., 1996; Besada et al., 2006). 
The synthesis of UDP-α,β-CH2 and 5-bromo-UTP-β,γ-CCl2 (Ko et al., 2008) yielded enzymatically stable 
nucleotides. The latter combines substitutions at the phosphate chain and the uracil nucleobase. The di-
uridine nucleotide Up3U (uridine 5’-triphosphate 5’’-uridine) was also equipotent with UDP. INS48823, an 
Up3U derivative, was slightly more potent than UDP, and experimental data indicated greater hydrolytic 
stability (Korcok et al., 2005). The CDP (cytidine 5'-diphosphate) derivatives N4-benzyloxy-CDP 
(MRS2964), N4-methoxy-CDP, and N4-methoxy-Cp3U (MRS2957) were reported to activate the P2Y6 
receptor with higher potency than the standard agonist UDP (Maruoka et al., 2010). These analogs were 
also selective for the P2Y6 receptor over the P2Y2 and P2Y4 receptors and showed hydrolytic stability. 
With the help of homology modeling of the P2Y6 receptor structure, it was shown that the P2Y6 receptor is 
preferentially activated by UDP derivatives with a South (S)-conformation of the ribose ring: 
(N)-methanocarba-UDP was completely inactive, but (S)-methanocarba-UDP was more potent than UDP 
(Costanzi et al., 2005; Besada et al., 2006). 
To date, the only known specific P2Y6 receptor antagonist is MRS2578, a di-isocyanate derivative 
(Mamedova et al., 2004). However, this compound inhibits the P2Y6 receptor activity in an irreversible 
manner.  
1.5 Purinergic signaling: the role of extracellular nucleosides and nucleotides in 
cell-to-cell communication 
 
 In the extracellular space, adenosine and nucleotides such as ATP, ADP, UTP, and UDP can act 
as autocrine or paracrine signaling molecules. They regulate numerous physiological functions depending 
on cell type and tissue (Abbracchio et al., 2006; Burnstock, 2006; Corriden and Insel, 2010). Several 
human cell lines have been shown to constitutively release ATP and UTP in the resting state (Lazarowski 
et al., 2000). Nucleotide release is balanced by extracellular nucleotide hydrolysis and 
transphosphorylation. Resting nucleotide concentrations are observed only in the nanomolar range. They 
are lower than the mere dilution by diffusion of molecules in a medium, with increasing distance from the 
secreting cells, would suggest. This can be explained with the activity of extracellular nucleotide-
hydrolyzing enzymes (Joseph et al., 2003). However, depending on cell type and stimulus, the transient 
local concentration of secreted nucleotides in close proximity to a cell surface can be high enough to be 
able to activate membrane-localized nucleotide receptors (Ostrom et al., 2000). Such signals serve as a 
means for several specialized physiological cell-to-cell communications. 
 There is solid evidence that ATP and its break-down product adenosine can act as a neural 
transmitter or co-transmitter in the central and peripheral nervous system (Burnstock, 2007 and 2008). 
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Together with glutamate, γ-aminobutyric acid and glycine, ATP is an integral part of the inter-glial and 
neuron-to-glia cell communication. Also, di-adenosine polyphosphates play a role, since high 
concentrations have been detected in synaptic terminals (Guzmán-Aranguez et al., 2007). ATP was 
shown to play a key role in nociception, to affect neuronal and non-neuronal cell growth and 
differentiation, and was found to be involved in several disorders of the central nervous system 
(Burnstock, 2007 and 2008; Giniatullin et al., 2013). In neurons, ATP, like other nucleotides, is stored in 
synaptic vesicles. Also, nucleotides and nucleosides are released from injured or dying neuronal and non-
neuronal cells. In brain, microglia perceive these signals, migrate towards their source and eventually 
engulf the dead cells (Koizumi et al., 2013). 
As a result of the typical intracellular ATP concentration of 3 – 10 mM, cell lysis results in high 
concentrations of ATP in the extracellular space. This has been well documented to affect a series of 
immune cell responses, ranging from chemotaxis to cytokine release, and to the promotion of 
inflammation (Bours et al., 2006; Jacob et al., 2013). This way, extracellular ATP at very high 
concentrations acts as a danger signal. At the same time, extracellular ATP is also an important 
modulator of immune responses (Trautmann, 2009), which balances inflammation and immune-tolerance 
(Di Virgilio et al., 2009; Vitiello et al., 2012). 
Cell death does, however, not necessarily involve cell lysis and the accompanying leakage of 
cytoplasmic content into the extracellular space. During the tightly controlled process of apoptosis, the 
cytoplasmic contents, including the high concentrations of intracellular nucleotides, are kept enclosed 
within the dying cells. This process allows for the removal of aged, damaged, or redundant cells without 
promoting inflammation. Apoptotic cells release ATP and UTP at nanomolar concentrations which both 
act as ‘find-me’ signals for phagocytes (Elliott et al., 2009). These phagocytes, mainly macrophages and 
dendritic cells, are responsible for the following clearance of the apoptotic cells. 
Nucleotides can further serve as signaling molecules in numerous physiological processes 
beyond the realms of the immune and nervous systems. In the vascular system for example, erythrocytes 
subjected to metabolic and mechanical stimuli release ATP, which is subsequently detected by P2Y 
nucleotide receptors of the vascular endothelial cells (Sprague et al., 1996; González-Alonso et al., 2002; 
Kalsi et al., 2012; González-Alonso, 2012). This eventually leads to the activation of nitric oxide (NO) 
synthases and vasodilatation. 
ADP release from platelets promotes thrombus formation by activating additional platelets, but 
increased concentrations of extracellular ADP trigger the production and the release of NO from platelets. 
This inhibits further recruitment of platelets, balancing the thrombus size (Lüthje et al., 1984; Freedman et 
al., 1997; Ku et al., 2007; Carroll et al., 2007).  
Mechanisms of nucleotide release. 
The release of nucleotides from intracellular vesicles is not restricted to neuronal cells. It can also 
be observed in several non-neuronal cells, like mast cells, platelets, and many epithelial cell types, like 
urothelial cells, vascular epithelial cells, and the biliary secreting cholangiocyte cells (Osipchuk and 
Cahalan, 1992; Guzmán-Aranguez et al., 2007; Taylor et al., 1998; Bodin and Burnstock, 2001; Knight et 
al., 2002; Gatof et al., 2003). In platelets, nucleotides like ATP, ADP, and the di-adenosine 
polyphosphates Ap3A, Ap4A, Ap5A, and Ap6A are stored in dense granules (Lüthje et al., 1983; Schlüter et 
al. 1994). In dense secretory granules of adrenal medullary chromaffin cells, the nucleotides ATP, ADP, 
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and AMP, as well as Ap4A, Ap5A, and Ap6A were detected (Rodriguez del Castillo et al., 1988; Pintor et 
al., 1992c). The accumulation of ATP in vesicles was shown to rely on the vesicular nucleotide 
transporter (VNUT) SLC17A9 (Sawada et al., 2008). Furthermore, exocytosis of ATP-containing 
lysosomes appears to be important for calcium (Ca2+) wave propagation between astrocytes (Zhang et 
al., 2007). 
Non-vesicular nucleotide release can be caused by mechanical stimulation, hypoxia, or receptor 
stimulation in many cell types (Forrester and Lind, 1969; Lazarowski et al., 1997b; Gerasimovskaya et al., 
2002; Abbrachio et al., 2006). Pannexin and connexin hemichannels were found to mediate ATP efflux 
(Figure 2; Kang et al., 2008; Huang et al., 2007). In concert with the subsequent autocrine or paracrine 
activation of P2 receptors, the non-vesicular nucleotide release is recognized as an important contributor 
to pro- and anti-inflammatory pathways, apoptosis, tissue regeneration, and stem cell differentiation, as 
well as ischemia, atherosclerosis, and even HIV infection (Adamson et al., 2014; Marenkova et al., 2014; 
Velasquez et al., 2014).  
Recent studies have extended the list of ATP-releasing membrane channels to volume-regulated 
anion channels (Hisadome et al., 2002) and voltage-dependent anion channels (Bell et al., 2003; Liu et 
al., 2008). The P2X7 receptor, an ATP-activated cation channel, can mediate the release of ATP through 
pannexin-1 channels (Pelegrin et al., 2006; Adamson et al., 2014) but not Connexin-43 hemichannels 
(Suadicani et al., 2008). 
 
                         
Figure 2: Nucleotide release and signaling during apoptosis and inflammation (Idzko et al., 2014).  
CD39 = E-NTPDase 1; CD73 = ecto-5'-nucleotidase. 
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Modulation of purinergic signaling by hydrolyzing and converting enzymes. 
The aforementioned enzymatic hydrolysis or conversion of extracellular nucleotides contributes to 
extracellular nucleotide signaling to the same degree as the nucleotide secretion itself. Rapid degradation 
of nucleotides can switch off signals and may additionally initiate other signaling pathways by creating 
new receptor-specific ligands (Figure 3). This also can locally restrict the occurrence of extracellular 
nucleotides (Joseph et al., 2003). This important modulation of the extracellular nucleotide signaling is 
realized by several groups of ecto-nucleotidases (Zimmermann et al., 2000).  
 
 
Figure 3: Schematic overview of nucleotide receptors and signal modulation via activity of 
nucleotide hydrolyzing enzymes (modified from Khakh et al., 2006). P2X = ionotrophic P2 nucleotide 
receptors; P2Y = metabotropic, G protein-coupled P2 nucleotide receptors; CAR = cAMP receptors; A = 
metabotropic, G protein-coupled P1 adenosine receptors. 
 
These enzymes, which are either soluble or membrane localized, are present in virtually every 
human tissue and may have a large spectrum of cell type-dependent physiological functions. Ecto-
nucleoside triphosphate diphosphohydrolases (E-NTPDases) hydrolyze nucleoside di- or triphosphates. 
E-NTPDase1, 2, 3, and 8 are membrane-localized, and have an extracellular catalytic activity. 
E-NTPDase4 - 7 activity is localized intracellularly (Robson et al., 2006). Ecto-nucleotide 
pyrophosphatase/phosphodiesterases (E-NPPs) can hydrolyze phosphodiester bonds and 
pyrophosphate (PPi) and exist in membrane localized and soluble forms (Goding et al., 2003). 
E-NPP1 - 3 convert ATP and ADP to AMP, PPi, and eventually ortho-phosphate (Pi), but they degrade 
also NAD+ to nicotinamide mononucleotide. Additionally, cAMP can be processed to AMP. E-NPP4 
recently was found to hydrolyze the di-nucleotide Ap3A to AMP and ADP and Ap4A to AMP and ATP 
(Albright et al., 2012).  
The ecto-5’-nucleotidases are considered to be a major source for the production of extracellular 
adenosine as they are actively cleaving nucleoside monophosphates into nucleosides and Pi 
(Zimmermann at al., 1992). The enzymes of the alkaline phosphatase family are able to perform the 
complete hydrolysis of nucleoside triphosphates into the corresponding nucleosides and phosphates 
without further contribution of other nucleotidases. 
In contrast to the nucleotide-hydrolyzing enzymes, nucleoside diphosphokinases and alkaline 
kinases elevate the concentration of nucleotides via transphosphorylation reactions (Lazarowski et al., 
1997a; Yegutkin et al., 2001). These enzymes catalyze the conversion of ATP plus UDP to ADP plus 
UTP or two molecules of ADP to ATP and AMP, respectively. 
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1.6  Aims of the project 
 
1. Characterization of the human P2Y11 receptor carrying the Ala-87-Thr mutation. 
Naturally occurring genetic polymorphisms of P2Y receptor genes may change functional 
characteristics of the receptors and thus provide an excellent opportunity to study the biochemical 
parameters of physiological and pathological nucleotide signaling. Here, we characterized a nucleotide 
polymorphism in the human P2RY11 gene, which results in an Ala-87-Thr amino acid change in the 
P2Y11 receptor protein. The impact of this mutation on P2Y11 receptor activity, as well as its mechanistic 
connection to the development of AMI, has been unknown so far. Therefore, this study should provide 
first functional insights.  
1.1 Investigation of nucleotide-induced P2Y11A87T receptor-mediated intracellular responses 
in comparison to the wildtype P2Y11 receptor. 
The P2Y11A87T receptor was expressed in 1321N1 astrocytoma and in HEK293 cells. In these cells, 
nucleotide-induced intracellular Ca2+ mobilization, cAMP generation, receptor internalization, as well as 
de- and resensitization of Ca2+ responses were investigated. The data were compared to those from the 
wildtype P2Y11 receptor.  
1.2 Generation of the P2Y11A87S and P2Y11A87Y receptors and investigation of intracellular 
responses in comparison to the P2Y11A87T receptor. 
The P2Y11A87S and P2Y11A87Y mutant receptors were generated additionally. We investigated 
nucleotide-induced intracellular Ca2+ responses, receptor internalization, and de- and resensitization of 
Ca2+ responses. This should help to elucidate whether the polarity of the amino acid at position 87 of the 
protein might be the cause for a putative change in receptor activity.  
1.3 Co-expression of the P2Y11A87T receptor with the P2Y1 receptor in the P2Y receptor-null 
background of 1321N1 astrocytoma cells. 
HEK293 cells endogenously express the P2Y1 receptor, which was reported to form functionally 
unique oligomers with the P2Y11 receptor. 1321N1 astrocytoma cells provide a P2Y receptor-null 
background and therefore are predestined for the analysis of isolated P2Y receptor functions and 
signaling. The co-expression of the P2Y1 and P2Y11A87T receptors in 1321N1 astrocytoma cells was 
used to confirm the results achieved with HEK293 cells. 
 
2. Evaluation of potency and receptor selectivity of novel synthetic nucleotides as agonists 
of the human P2Y11 and P2Y6 receptors. 
Human P2Y receptors are interesting targets for drug development since they are connected to many 
physiological and pathological processes. Thus, the next aim was to gain new insights into structure-
activity relationships of novel synthetic ATP-derived nucleotides as agonists of the human P2Y11 receptor. 
In addition, UDP-derived nucleotide analogs were evaluated as agonists of the human P2Y6 receptor. 
The novel nucleotide compounds were synthesized in our collaborators laboratory (Prof. Bilha Fischer, 
Department of Chemistry, Gonda-Goldschmied Medical Research Center, Bar-Ilan University, Ramat-
Gan, Israel). The nucleotides were tested on 1321N1 astrocytoma cells expressing these receptors 
mostly as C-terminal GFP-fusion proteins. GFP-labeled P2Y receptors have successfully been used 
before in several physiological and pharmacological studies (Tulapurkar et al., 2004; Ecke et al., 2006; 
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Tulapurkar et al., 2006; Zylberg et al., 2007). Nucleotide potency at the P2Y11 and P2Y6 receptors was 
analyzed by measuring the nucleotide-induced rise of intracellular Ca2+. Since the human P2Y11 receptor 
is coupled to Gs signaling, the P2Y11 receptor-mediated elevation of cAMP levels was investigated for 
selected ATP analogs.  
2.1 Investigation of 2-propylthio-substituted analogs of ATP at the human P2Y11 receptor. 
The novel P2Y11 receptor agonists investigated here were based on the structure of the very potent 
P2Y11 receptor agonist AR-C67085 (Communi et al., 1999). This ATP derivative features a propylthio-
group at the C2 position of the adenine nucleobase and a CCl2 group between the β- and the 
γ-phosphate. By introducing an additional borano or thio substitution of a non-bridging oxygen at the 
α-phosphate, we created a new chiral center. This should increase nucleotide selectivity since the 
stereoselectivity of the P2Y11 receptor is opposite to that of the closest homolog, the adenine nucleotide-
preferring P2Y1 receptor. Furthermore, we expected a beneficial effect on hydrolytic stability and 
nucleotide potency, as these effects have been reported before for several other nucleotide analogs. 
2.2 Investigation of 5-OMe-substituted analogs of UDP at the human P2Y6 receptor. 
On the P2Y6 receptor, a series of mono- and di-nucleotide analogs of UDP, which carried an OMe-
substitution at the C5 position of the nucleobase, was tested regarding nucleotide selectivity and potency. 
Additionally, several of the tested analogs featured Pα-substitutions. This should increase hydrolytic 
stability and nucleotide potency, despite the fact that a diastereoselectivity has not been reported before 
for the P2Y6 receptor. 
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2. Materials and methods 
2.1 Materials 
2.1.1 Expression vectors 
 
For C-terminal GFP-fusion protein expression in mammal cell lines, the 4.7 kb pEGFP-N1 vector 
(Clontech Laboratories Inc., Palo Alto, CA, USA) with a kanamycin/neomycin resistance cassette was 
used. The 5.5 kb pcDNA 3.1/myc-His vector (Life Technologies Corporation, Carlsbad, CA, USA) with an 
ampicillin/neomycin resistance cassette was used for expression of proteins with a C-terminal myc-His 
tag in mammal cell lines. 
2.1.2 Chemicals, reagents, and enzymes 
 
Penicillin and streptomycin were used to supplement cell culture media and were purchased from 
Biochrom AG (Berlin, Germany). G418 (geneticine) was used for culturing of mammal cell lines 
transfected with the pEGFP-N1 expression vector and was obtained from Merck Chemicals GmbH 
(Schwalbach/Ts., Germany). Fura 2/AM for single-cell Ca2+ measurements was supplied by Life 
Technologies Corporation (Carlsbad, CA, USA). For the lipofection of mammal cell lines, FuGENE 6 
Transfection Reagent and DOTAP by Roche Diagnostics GmbH (Mannheim, Germany) were used. 
MATra-A nanoparticles for magnet-assisted transfection were obtained from Iba GmbH (Göttingen, 
Germany). Para-formaldehyde used for cell fixation and the nucleotides used for P2Y receptor activation 
(ATP, UDP, UTP, 2-MeS-ADP, and BzATP) were supplied by Sigma-Aldrich (St. Louis, MO, USA). The 
P2Y1 receptor antagonist MRS2179 and the P2Y6 receptor antagonist MRS2578 were produced by 
Sigma-Aldrich and Tocris Bioscience (Bristol, UK). The Pfu polymerase, the restriction enzymes DpnI, 
HindIII, and BamHI, as well as the mouse monoclonal α-Myc and Alexa555 goat anti–mouse antibodies 
used for immunocytochemistry were supplied by Thermo Fisher Scientific Inc. (Waltham, MA, USA). All 
other chemicals used for cell culture and single-cell Ca2+ measurements were obtained from Carl Roth 
GmbH (Karlsruhe, Germany).  
2.1.3 Primers for site-directed mutagenesis 
 
MHP2Y11GFPA87Tup: 5’-CTG CCC CCG CTG GCC ACC TAC CTC TAT CCC-3’ 
  
MHP2Y11GFPA87Tlow: 5’-GGG ATA GAG GTA GCT GGT CAG CGG GGG CAG-3’ 
  
MHP2Y11GFPA87Sup: 5’-CTG CCC CCG CTG GCC AGC TAC CTC TAT CCC-3’ 
  
MHP2Y11GFPA87Slow: 5’-GGG ATA GAG GTA GCT GGC CAG CGG GGG CAG-3’ 
  
MHP2Y11GFPA87Yup: 5’-CTG CCC CCG CTG GCC TAT TAC CTC TAT CCC-3’ 
  
MHP2Y11GFPA87Ylow:  5’-GGG ATA GAG GTA GCT ATA CAG CGG GGG CAG-3’ 
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2.1.4 Sequencing primers 
 
THP2Y11FW1: 5’-ACC TGC ATC AGC CTC AAC CGC-3’ 
  
THP2Y11FW2: 5’-TGG CCC TCT ACG CCA GCT CCT A-3’ 
  
THP2Y11FW3: 5’-TGT GTC CAC CCT CTA CTC TAC A-3’ 
  
THP2Y11RV1: 5’-AGC GGT TGA GGC TGA TGC AGG T-3’ 
  
THP2Y11RV2: 5’-TAG GAG CTG GCG TAG AGG GCC A-3’ 
  
THP2Y11RV3: 5’-TGT AGA GTA GAG GGT GGA CAC A-3’ 
 
2.2 Cell media 
 
Dulbecco’s modified Eagle’s medium (DMEM) for 1321N1 astrocytoma cell culture:  
DMEM (Biochrom AG, Berlin, Germany) was supplemented with 10% (v/v) fetal calf serum (FCS; PAA 
Laboratories GmbH, Pasching, Austria), 100 U/ml penicillin, and 100 U/ml streptomycin. 
DMEM/Ham’s F-12 (1:1) for HEK293 cell culture:  
Dulbecco’s MEM/Ham’s F-12 (1:1) (Biochrom AG, Berlin, Germany) was supplemented with 10% (v/v) 
FCS, 100 U/ml penicillin, and 100 U/ml streptomycin. 
LB medium for bacterial culture: 
10 g tryptone, 5 g yeast extract, 10 g NaCl, 15 g agar (for plates), pH 7.0. 
SOC medium for bacterial transformation: 
5 g tryptone, 1.25 g yeast extract, 0.15 g NaCl, 0.125 g KCl, 1 M glucose, 1 M MgCl2, 1 M MgSO4. 
2. Materials and methods 
 
21 
2.3 Buffers and solutions 
 
 
 
1 x NaHBS (+ Ca2+): 
145 mM NaCl, 5.4 mM KCl, 1 mM MgCl2, 
25 mM glucose, 20 mM HEPES, 
1.8 mM CaCl2, pH 7.4. 
 
1 x PBS: 
137 mM NaCl, 2.6 mM KCl, 8.1 mM Na2HPO4, 
1.4 mM KH2PO4, pH 7.4. 
 
4% PFA solution: 
4% (v/v) PFA (paraformaldehyde), 
120 mM Na2HPO4, 4% (w/v) saccharose, 
pH 7.4. 
 
5 x KCM solution: 
500 mM KCl, 150 mM CaCl2, 250 mM MgCl2. 
 
Embedding medium: 
100 mg Dabco (1,4-Diazabicyclo[2.2.2]octane) 
was dissolved in 100 µl PBS (pH 8.9) using 
vortexer and thermomixer. 2.45 ml glycerol and 
2.45 ml Vectashield were added subsequently. 
The solution was incubated under constant 
shaking at 4 °C in darkness. For storage, the 
reaction tube was wrapped in aluminum foil 
and kept at 4 °C. 
FSBB (fetal serum blocking buffer): 
17% (v/v) FCS, 20 mM Na2HPO4, 
450 mM NaCl, 0.3% (v/v) Triton X-100. 
 
High salt buffer: 
500 mM NaCl, 20 mM Na2HPO4. 
 
Low salt buffer: 
150 mM NaCl, 10 mM Na2HPO4. 
 
Solutions for DNA mini preparation: 
Solution 1: 50 mM glucose, 25 mM Tris/HCl 
pH 8.0, 10 mM EDTA pH 8.0, 
100 µg/ml RNAse. 
Solution 2: 0.2 M NaOH, 1% (w/v) SDS. 
Solution 3: 3 M CH3CO2K, 11.5% (v/v) 
CH3COOH. 
 
Tris-EDTA (TE): 
10 mM Tris/HCl pH 8.0, 0.2 mM EDTA. 
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2.4 Methods 
2.4.1 KCM-transformation of Escherichia coli bacteria 
 
For transformation, 1 - 10 µl DNA were mixed with 20 µl 5 x KCM solution and sterile bidest 
H2O was added to a final volume of 100 µl. 100 µl of KCM competent DH5α cells were thawed on ice 
and then incubated with the DNA/KCM solution for 30 min on ice. Afterwards, the cells were kept at 
room temperature (RT) for additional 10 min before 800 µl of the pre-warmed (37 °C) SOC medium 
were added. The cells were gently mixed (200 rpm) in a cell incubator for 1 h at 37 °C. After the 
incubation, the cells were plated on agarose dishes containing the selection antibiotic. The dishes 
were incubated overnight at 37 °C. Positive clones were selected and sub-cultured. 
2.4.2 DNA extraction (mini preparation) 
 
Transfected DH5α clones were picked and incubated in 5 ml liquid LB medium supplemented 
with the selection antibiotic. The cells were incubated overnight at 37 °C and mixed gently with 
200 rpm. The next day, 1.5 ml of the cell suspension were transferred to a reaction tube and 
centrifuged briefly (30 s). The cell pellet was resuspended in 100 µl of solution 1. Cell lysis was 
induced by adding 200 µl of solution 2. The sample was mixed very carefully and incubated at RT for 
5 min. 150 µl of solution 3 were added to the now clear and viscous cell suspension. Next, the 
suspension was kept on ice for 15 min with occasional gentle mixing. After this incubation step, the 
suspension was centrifuged at maximum speed (13.000 rpm) for 15 min at RT. The clear supernatant 
was transferred to a fresh reaction tube, mixed with 300 µl isopropanol in order to precipitate the DNA, 
and incubated for 5 min at RT. The suspension was then centrifuged at maximum speed for 10 min at 
RT. The supernatant was discarded and the remaining DNA-containing pellet was washed with 500 µl 
of 70% ethanol to remove excess salt. The sample was then centrifuged at maximum speed for 10 min 
at RT and the supernatant was discarded. The pellet was dried at RT or using a heating block 
(preheated to 40 °C). Finally, the DNA pellet was solubilized in 50 µl bidest H2O or TE buffer and 
stored at -20 °C.  
2.4.3 Site-directed mutagenesis 
 
For site-directed mutagenesis, the QuickChange Site-Directed Mutagenesis Kit (Agilent 
Technologies Inc., Santa Clara, CA, USA) was used. The mutagenesis primers were designed 
according to the manual. A Pfu polymerase was used instead of the Pfu Turbo polymerase suggested 
by the manufacturer. The PCR cycler program was designed as follows: initial denaturation at 98 °C 
for 30 s, second denaturation at 95 °C for 30 s, primer annealing at 55 °C for one min, polymer 
extension at 70 °C for 12 min. The steps 2 to 4 were repeated 16 times. After mutagenesis PCR, 1 µl 
of the DpnI restriction enzyme was added to the PCR product in order to digest methylated template 
plasmid DNA. Competent DH5α E.coli cells were then transformed as described above with the 
pEGFP-N1 expression vector containing the mutated P2RY11 receptor cDNA insert. The cells were 
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plated on kanamycin containing agarose plates and incubated at 37 °C. Clones were picked 10 to 12 h 
later and transferred to liquid LB medium for overnight growth at 37 °C before the plasmid DNA was 
extracted. The extracted DNA was test-digested with HindIII and BamHI restriction enzymes in order 
to verify correct fragment sizes in a 1% agarose gel. The positive clones were selected for 
sequencing. 
2.4.4 Cell culture and transfection of human cell lines 
 
Using the pEGFP-N1 expression vector, C-terminal GFP constructs of human P2Y receptors 
were stably expressed in human 1321N1 astrocytoma cells or in HEK293 cells. The P2Y1-myc/His 
receptor was expressed in 1321N1 astrocytoma cells using the pcDNA 3.1/myc-His expression vector. 
1321N1 astrocytoma cells were transfected using FuGENE 6 Transfection Reagent and 
HEK293 cells using DOTAP Liposomal Transfection Reagent. Transfected HEK293 cells were 
selected with 0.5 mg/ml G418 and grown in DMEM/Ham’s F12 (1:1) cell culture medium. Transfected 
1321N1 astrocytoma cells were selected with 1.0 mg/ml G418 and grown in DMEM cell culture 
medium. All cultures were maintained in cell culture incubators with humidified atmosphere at 37 °C 
and 5% CO2. The expression of the receptors by the cells was confirmed by detection of the GFP 
fluorescence using a confocal fluorescence microscope and/or the elevation of [Ca2+]i after stimulation 
with the physiological standard nucleotide agonists of the respective P2Y receptor. 
FUGENE 6 lipofection of 1321N1 astrocytoma cells was performed as follows: The cells were 
seeded in cell culture dishes (diameter 6 cm) one day prior to the transfection and grown to 50% - 
80% confluency. For transfection, FuGENE 6 Transfection Reagent was mixed with DMEM (final 
volume 200 µl) and DNA in 3:1 (3 µl FUGENE 6 and 1 µg DNA), 3:2 (3 µl FUGENE 6 and 2 µg DNA), 
and 6:1 (6 µl FUGENE 6 and 1 µg DNA) ratios. Before the addition of DNA, FUGENE 6 was mixed 
with medium and incubated for 5 min at RT. The addition of DNA to the mixture was followed by a 
30 min incubation at RT. Afterwards, the transfection mixtures were added dropwise to the cells 
followed by 1.8 ml medium. The cells were kept in the incubator for 4 - 5 h. After this, 2 ml of cell 
culture medium were added and the cells were incubated overnight. The next day, the medium was 
renewed and G418 was added. 
DOTAP lipofection of HEK293 cells was performed as follows: The cells were seeded in cell 
culture dishes (diameter 6 cm) one day prior to the transfection and grown to 50% - 80% confluency. 
5 µg DNA were mixed with 50 µl HEPES (20 mM) and 30 µl DOTAP were mixed with 70 µl HEPES 
(20 mM). The DNA and DOTAP solutions were then combined and incubated for 30 min at RT before 
the addition of 3 ml DMEM/Ham’s F12 (1:1) cell culture medium. The final transfection solution was 
added and the cells were incubated at 37 °C. After 6 - 8 h, the transfection solution was replaced by 
cell medium and the cells were then incubated for additional 10 h. After that, the cell medium was 
complemented with G418. 
Magnet-assisted transfection with MATra-A nanoparticles was used for co-expression of the 
P2Y1 and P2Y11 or P2Y11A87T receptors in 1321N1 astrocytoma cells. The cells were seeded in cell 
culture dishes (diameter 6 cm) two days prior to the transfection and grown to 50% - 80% confluency. 
For double transfections, 2.5 µg of each plasmid DNA (5 µg for single transfections) were diluted in 
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serum-free DMEM cell medium to a final volume of 400 µl. 6.6 µl of the MATra-A solution were added 
carefully. After 20 min incubation at RT, the transfection mixture was added drop wise to the cells and 
complemented with 4 ml serum-free DMEM. The cell culture dishes were then placed on magnet 
plates and kept in the cell incubator for 15 min. After this step, the medium was changed to DMEM 
containing 10% FCS and the cells were incubated for about 48 h before measurement. 
All transfected HEK293 and 1321N1 astrocytoma cell cultures used in the experiments were 
derived from the same stock wild type cell cultures to guarantee equal conditions for all experiments. 
2.4.5 Single-cell Ca2+ measurements 
 
1321N1 astrocytoma or HEK293 cells expressing the P2Y-GFP receptor or wildtype control 
cells were seeded on cover slides (diameter 22 mm) and grown for two days to approximately 80% 
density. The cover slides used for HEK293 cell growth were coated with poly-L-lysine to ensure cell 
adhesion during measurement. Prior to measurement, the cells were incubated in NaHBS buffer 
complemented with 2 μM of the ratiometric Ca2+-sensitive dye Fura 2/AM for 30 min at 37 °C. If 
necessary, a P2Y receptor antagonist was added to the incubation buffer. 
For standard single-cell Ca2+ measurements, used for the determination of the EC50 values of 
nucleotides, the cells were superfused (1 ml/min, 37 °C) with NaHBS buffer containing the agonist 
and/or antagonist in the desired concentration. Only cells with a clear, plasma membrane-localized 
GFP-signal and with the typical Ca2+ response kinetics upon agonist pulse application were included in 
the data analysis. The amplitudes of the intracellular Ca2+ responses were calculated as described 
below.  
For the analysis of Ca2+ response desensitization and resensitization, HEK293 cells 
expressing the P2Y11, the P2Y11A87T, or the P2Y11A87S receptor were incubated with 100 µM ATP 
for the prolonged period of 30 min ( 
Figure 19). This is sufficient to induce receptor internalization in P2Y11 receptor-expressing 
cells (Ecke et al., 2008). To allow receptor resensitization, the cells were superfused with nucleotide-
free NaHBS buffer for 60 min. Finally, a brief 1 min application of 100 µM ATP was used to determine 
the extent of the recovery of the intracellular Ca2+ response.  
Intracellular Ca2+ measurements with 1321N1 astrocytoma cells co-expressing the P2Y1 and 
P2Y11 or P2Y11A87T receptors were performed as follows: Cells with P2Y11 or P2Y11A87T receptor 
expression, as verified by GFP fluorescence, were selected for analysis and challenged with 1 µM 
BzATP. After a recovery period of at least 2 min, 1 µM 2-MeS-ADP was added to verify the co-
expression of the P2Y1-myc/His receptor. GFP-positive cells responding to the 2-MeS-ADP stimulus 
were considered as P2Y1/P2Y11 or P2Y1/P2Y11A87T co-expressing cells.  
For the measurement of the nucleotide-induced Ca2+ responses, the ratio of the 510 nm 
emissions of Fura 2 after subsequent excitations at 340 nm and 380 nm (F340 nm / F380 nm) was 
determined. Free intracellular Ca2+ binds to Fura 2 and causes increased 340 nm excitation and 
decreased 380 nm excitation. The reduction of [Ca2+]i has the opposite effect. Thus, changes of the 
F340 nm / F380 nm ratio can be used to determine the amplitudes of the nucleotide-induced 
intracellular Ca2+ responses, as the changes in the excitation spectrum of Fura 2 directly correlate to 
the intracellular Ca2+ concentration. 
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The experiments were conducted using a TILL Photonics Polychrome IV setup (FEI Munich 
GmbH, Gräfelfing, Germany) with a Zeiss Axiovert 135 inverted fluorescence microscope (Carl Zeiss 
AG, Oberkochen, Germany). The concentration-response curves and EC50 values were derived from 
the average response amplitudes using SigmaPlot (Systat Software Inc., San Jose, CA, USA). As 
previously reported, the GFP-tagged P2Y receptors are suitable for pharmacological and physiological 
studies and were found to be functionally indistinguishable from P2Y receptors without GFP tag 
(Tulapurkar et al., 2004; Ecke et al., 2006; Tulapurkar et al., 2006; Zylberg et al., 2007).  
2.4.6 cAMP measurements 
 
 Cells expressing the P2Y11 or P2Y11A87T receptor were grown in cell culture dishes (diameter 
6 cm) to circa 70% confluency. The cells were incubated in NaHBS buffer containing 500 µM isobutyl-
methyl-xanthine (IBMX; a non-specific inhibitor of cAMP phosphodiesterases) for 30 min at 37 °C. 
Nucleotide was then added in the desired concentration in order to activate the P2Y receptors and the 
cells were incubated for 10 min at 37 °C. The cells were lysed using 0.1 M HCl, scraped from the 
dishes and sonicated briefly. 100 µl of the cell extract were kept for the determination of total protein 
concentration using a standard Bradford protein assay. The cAMP content of the cells was determined 
with the direct cyclic AMP enzyme immunoassay kit from ENZO Life Sciences Inc. (Farmingdale, NY, 
USA). The following steps were conducted according to the manufacturer’s manual.  
2.4.7 Nucleotide-induced receptor internalization 
 
For the investigation of the nucleotide-induced internalization of the P2Y11, P2Y11A87T, 
P2Y11A87S, and P2Y11A87Y receptors, the expressing HEK293 cells were grown on a cover slide 
(diameter 22 mm) to approximately 70% confluency. After incubation with the respective nucleotide for 
60 min, the cells were fixed with 4% PFA for 30 min at RT. After this, the cover slides were washed 3 
times with PBS, placed upside down on a glass slide with a drop of embedding medium and sealed 
with nail polish. The localization of GFP fluorescence was detected using a LSM 510 META laser 
scanning confocal microscope (Carl Zeiss AG, Oberkochen, Germany) using a 488 nm argon/krypton 
laser and a 505–530 nm band pass filter. 
2.4.8 Immunocytochemistry 
 
1321N1 astrocytoma cells transfected with the magnet-assisted transfection method were 
fixed with 4% PFA (15 min at RT). The cells were kept overnight in 120 mM Na2HPO4 solution. The 
cover slides were then washed once with low salt buffer and twice with high salt buffer for 10 min, 
respectively. 60 µl FSBB for blocking and permeabilization were added per cover slide and incubated 
for 20 min. Subsequently, the primary antibody (mouse monoclonal α-Myc, 1:100 in FSBB) was added 
to the cover slides and kept overnight at 4 °C. The next day, the cover slides were washed 3 x 10 min 
with high salt buffer. Following these washing steps, the secondary antibody (Alexa555 goat anti–
mouse, 1:200 in FSBB) was applied, and the cells were incubated in darkness for 1.5 h at RT. The 
cover slides were then washed with high salt buffer, followed by 120 mM Na2HPO4 solution, and PBS 
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for 10 min, respectively. The cover slides were placed upside down on a glass slide with a drop of 
embedding medium and sealed with nail polish. The localization of fluorescence was detected using a 
LSM 510 META laser scanning confocal microscope. GFP fluorescence was detected with a 488 nm 
argon/krypton laser in conjunction with a 505–530 nm band pass filter. Alexa555 fluorescence was 
detected using a 543 nm helium/neon laser and a 560 nm long pass filter.  
2.4.9 Statistical analysis 
 
Statistical analysis was performed with IBM SPSS 21 (International Business Machines Corp., 
Armonk, NY, USA) using the One-Way ANOVA test followed by a Dunnett-T3 post-hoc test. For the 
cAMP measurements, the mean values given are based on least two samples with the majority of 
experiments carried out 3 - 12 times. The average cAMP levels induced by corresponding 
concentrations of nucleotides were compared statistically. Nucleotide concentrations relevant for the 
calculation of EC50 values were used in at least three independent single-cell Ca2+ measurements with 
an average of 10 - 20 cells per experiment. Statistical differences between individual concentration-
response curves were calculated by comparing the average amplitudes of the Ca2+ responses 
(Δ F340 nm / F380 nm) to corresponding concentrations of nucleotide. The comparative analysis of 
Ca2+ responses in GFP-negative and GFP-positive HEK293 cells included 2 - 3 independent 
experiments with 5 - 40 cells per experiment. The average amplitudes of the Ca2+ responses to 
different nucleotides from GFP-negative and GFP-positive cells were compared statistically. The Ca2+ 
measurements with 1321N1 astrocytoma cells co-expressing the P2Y1 and P2Y11 or P2Y11A87T 
receptors were conducted 3 - 9 times with 4 to 13 cells per experiment. The average amplitudes of the 
Ca2+ responses to BzATP of cells co-expressing the P2Y11A87T and the P2Y1 receptor were 
compared with the corresponding responses of cells co-expressing the wildtype P2Y11 and the P2Y1 
receptor. In addition, these responses were statistically compared with BzATP-induced responses of 
1321N1 cells single-expressing the P2Y11A87T receptor, P2Y11 receptor, or P2Y1 receptor.  
Fluorescence intensities of GFP tags, which were C-terminally fused to the wildtype and 
mutant P2Y11 receptors expressed in HEK293 cells (n = 59 – 80 cells), were quantified in fixed cell 
preparations using the histogram function of the LSM510 Meta software of the LSM 510 META laser 
scanning confocal microscope. 
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3. Results 
 
3.1 Characterization of the human P2Y11 receptor with 
the Alanine-(87)-Threonine mutation 
 
3.1.1 Nucleotide potencies at the wildtype P2Y11 receptor, compared to mutant 
P2Y11A87T, P2Y11A87S, or P2Y11A87Y receptors expressed in 1321N1 
astrocytoma and HEK293 cells 
 
In order to study the P2Y11A87T receptor function, the receptor was expressed by us in 
1321N1 astrocytoma cells and the pharmacological profile was determined using single-cell Ca2+ 
measurements (Haas et al., 2014). The data were compared to results obtained with the wildtype 
P2Y11 receptor. 1321N1 astocytoma cells lack endogenous P2Y receptor expression and are, 
therefore, frequently used for the investigation of P2Y receptors. Additionally, we used HEK293 cells 
for receptor expression. It was shown before (Ecke et al., 2008) that in HEK293 cells the P2Y11 
receptor shows new pharmacological and functional properties, which are due to the interaction with 
endogenous P2Y1 receptors.  
BzATP is a potent agonist for the P2Y11 receptor, and specific within the P2Y receptor family. 
In 1321N1 astrocytoma cells, no differences in the concentration-dependent intracellular Ca2+ 
responses to BzATP were detected between the P2Y11 and the P2Y11A87T receptor (Figure 4A). With 
0.8 +/- 0.1 µM for the P2Y11 receptor and 0.9 +/- 0.07 µM for the P2Y11A87T receptor, the EC50 values 
were virtually identical (Table 1). 
In sharp contrast, the P2Y11A87T receptor expressed in HEK293 cells is completely 
insensitive to BzATP of up to 100 µM (Figure 4B). However, at the wildtype P2Y11 receptor expressed 
in HEK293 cells the EC50 value of BzATP of 1.0 +/- 0.05 µM is very similar to that in 1321N1 
astrocytoma cells (Table 2).  
In order to investigate whether amino acid polarity at position 87 or amino acid size is the 
cause for altered receptor functionality, the P2Y11A87S and P2Y11A87Y receptors were generated and 
expressed in HEK293 cells. BzATP was a potent agonist for both receptors with EC50 values of 
0.8 +/- 0.06 µM for the P2Y11A87S receptor and 1.6 +/- 0.1 µM for the P2Y11A87Y receptor (Table 2). 
The maximal response amplitude to BzATP of the P2Y11A87S receptor, however, was 30% higher 
(P < 0.01) than that of the P2Y11A87Y receptor (Figure 4C). The P2Y11A87Y receptor showed maximal 
responses comparable to the wildtype P2Y11 receptor.   
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Figure 4: Concentration-response curves for the rise of [Ca2+]i induced by BzATP in 1321N1 
astrocytoma cells and HEK293 cells expressing the P2Y11A87T, P2Y11A87S, P2Y11A87Y, or 
wildtype P2Y11 receptors. Responses were induced in A: 1321N1 astrocytoma cells expressing the 
human P2Y11 or P2Y11A87T receptor, in B: HEK293 cells expressing the human P2Y11 or P2Y11A87T 
receptor, and in C: HEK293 cells expressing the human P2Y11A87S or P2Y11A87Y receptor. The cells 
were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence 
(Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of experiments and 
analyzed cells are given in methods. ** = significant differences (P < 0.01) of Ca2+ response 
amplitudes to the respective concentrations of nucleotides. 
 
 The human P2Y11 receptor is activated by 2-MeS-ADP only at high concentrations. This was 
shown with P2Y11 receptors expressed in 1321N1 astrocytoma cells (Figure 5A), where 2-MeS-ADP 
has a high EC50 value of 24.2 +/- 0.3 µM (Table 1). The EC50 value for 2-MeS-ADP at the P2Y11A87T 
receptor expressed in 1321N1 astrocytoma cells was similarly high with 35.6 +/- 0.001 µM. However, 
2-MeS-ADP is a very potent agonist at the human P2Y1 receptor expressed in 1321N1 astrocytoma 
cells with a very low EC50 value of 0.33 +/- 0.18 nM (Figure 5D). 
 Due to the endogenous P2Y1 receptor expression, HEK293 wildtype cells react strongly to 
2-MeS-ADP (Figure 5B) with a low EC50 value of 0.04 +/- 0.006 µM (Table 2). Remarkably, in HEK293 
cells expressing the P2Y11 receptor the EC50 value of 2-MeS-ADP increased to 0.14 +/- 0.01 µM. 
Expression of the P2Y11A87T receptor even further increased the EC50 value to 1.2 +/- 0.3 µM 
(P < 0.01). The potency of 2-MeS-ADP at HEK293 cells expressing the P2Y11A87S or P2Y11A87Y 
receptor (Figure 5C) was on about the same level with the wildtype P2Y11 receptor 
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(EC50 = 0.5 +/- 0.09 µM and 0.1 +/- 0.04 µM, respectively). Again, the P2Y11A87S receptor showed an 
about 40% higher (P < 0.01) maximal response amplitude than the P2Y11A87Y receptor. The latter 
receptor displayed maximal Ca2+ responses comparable to that of the P2Y11A87T receptor and the 
wildtype P2Y11 receptor. 
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Figure 5:  Concentration-response curves for the rise of [Ca2+]i induced by 2-MeS-ADP in 
1321N1 astrocytoma cells and HEK293 cells expressing P2Y11A87T, P2Y11A87S, P2Y11A87Y, or 
wildtype P2Y11 receptors. Responses were induced in A: 1321N1 astrocytoma cells expressing the 
human P2Y11 or P2Y11A87T receptor, in B: HEK293 cells expressing the human P2Y11 or P2Y11A87T 
receptor, in C: HEK293 cells expressing the human P2Y11A87S or P2Y11A87Y receptor, and 
in D: 1321N1 astrocytoma cells expressing the human P2Y1 receptor. The cells were pre-incubated 
with 2 µM Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, 
as described in methods. Numbers of experiments and analyzed cells are given in methods.  
** / * = significant differences (P < 0.01; P < 0.05, respectively) of Ca2+ response amplitudes to the 
respective concentrations of nucleotides; B: significant differences of Ca2+ response amplitudes to 
respective concentrations of nucleotides mediated by the P2Y11 and the P2Y11A87T receptors. 
 
 BzATP and 2-MeS-ADP are synthetic nucleotides. Therefore the physiological P2Y receptor 
ligand ATP was additionally used to investigate the intracellular Ca2+ response amplitudes using 
1321N1 astrocytoma cells and HEK293 cells (Figure 6). The P2Y11 and P2Y11A87T receptors 
expressed in 1321N1 astrocytoma cells (Figure 6A) yield very similar EC50 values for ATP with 
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2.6 +/- 0.4 µM and 2.8 +/- 0.3 µM, respectively (Table 1). For HEK293 cells expressing the P2Y11 
receptor (Figure 6B), the EC50 value of 1.8 +/- 0.08 µM for ATP was identical to the EC50 value of 
1.8 +/- 0.02 µM at HEK293 wildtype cells (Table 2). In HEK293 cells expressing the P2Y11A87T 
receptor (Figure 6B), however, the EC50 value was significantly (P < 0.01) increased to 2.8 +/- 0.2 µM. 
The P2Y11A87S and P2Y11A87Y receptors expressed in HEK293 cells (Figure 6C) show similarly 
increased EC50 values for ATP (2.9 +/- 0.3 µM and 3.5 +/- 0.5 µM, respectively). 
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Figure 6: Concentration-response curves for the rise of [Ca2+]i induced by ATP in 1321N1 
astrocytoma cells and HEK293 cells expressing the P2Y11A87T, P2Y11A87S, P2Y11A87Y, or 
wildtype P2Y11 receptors. Responses were induced in A: 1321N1 astrocytoma cells expressing the 
human P2Y11 or P2Y11A87T receptor, in B: HEK293 cells expressing the human P2Y11 or P2Y11A87T 
receptor, and in C: HEK293 cells expressing the human P2Y11A87S or P2Y11A87Y receptor. The cells 
were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence 
(Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of experiments and 
analyzed cells are given in methods. ** = significant differences (P < 0.01) of Ca2+ response 
amplitudes to the respective concentrations of nucleotides. 
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Table 1: Potencies (EC50 values in µM) of BzATP, 2-MeS-ADP, and ATP at the human wildtype 
P2Y11 and mutated P2Y11A87T receptor expressed in 1321N1 astrocytoma cells.  
Data were derived from concentration-response curves given in Fig. 4 - 6.  
 
Nucleotide 
 
1321N1 astrocytoma cells 
 Intracellular Ca2+ response (EC50 (µM) +/- SEM) 
P2Y11 P2Y11A87T 
BzATP 
(Fig. 4A) 
 0.8 +/- 0.1 0.9 +/- 0.07 
2-MeS-ADP 
(Fig. 5A) 
 24.2 +/- 0.3 35.6 +/- 0.001 
ATP 
(Fig. 6A) 
 2.6 +/- 0.4 2.8 +/- 0.3 
 
 
Table 2: Potencies (EC50 values in µM) of BzATP, 2-MeS-ADP, and ATP at the human wildtype 
P2Y11 receptor and the mutated P2Y11A87T, P2Y11A87S, and P2Y11A87Y receptors expressed in 
HEK293 cells.  
Data were derived from concentration-response curves given in Fig. 4 - 6. 
 
Nucleotide 
 
HEK293 cells 
 Intracellular Ca2+ response (EC50 (µM) +/- SEM) 
P2Y11 P2Y11A87T P2Y11A87S P2Y11A87Y 
 Control: 
wildtype cells 
(Fig. 7) 
BzATP 
(Fig. 4) 
 1.0 
+/- 0.05 
n.r. 
0.8 
+/- 0.06 
1.6 
+/- 0.1 
 
n.r. 
2-MeS-ADP 
(Fig. 5) 
 0.14 
+/- 0.01 
1.2 
+/- 0.3 
0.5 
 +/- 0.09 
0.1 
+/- 0.04 
 0.04 
 +/- 0.006 
ATP 
(Fig. 6) 
 
 
1.8 
+/- 0.08 
 
2.8 
+/- 0.2 
 
2.9 
+/- 0.3 
 
3.5 
+/- 0.5 
 
 1.8 
+/- 0.02 
 
 
 
 
Major conclusions 
 
The P2Y11 and P2Y11A87T receptors show identical Ca2+ responses in 1321N1 cells. 
 
In HEK293 cells, the P2Y11A87T receptor cannot be activated by BzATP. 
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Several human P2Y receptors can be activated by adenine or uridine nucleotides. Thus, a 
technical control experiment was conducted using HEK293 wildtype cells. The intracellular Ca2+ 
responses induced by ATP, BzATP, 2-MeS-ADP, UTP, or UDP were used to evaluate the presence of 
endogenously expressed P2 receptors. In HEK293 wildtype cells, the P2Y1 receptor specific agonist 2-
MeS-ADP induced a strong Ca2+ response (Figure 7), thus verifying the presence of endogenous P2Y1 
receptors. BzATP is unable to induce Ca2+ responses for concentrations of up to 100 µM, 
demonstrating the absence of endogenous P2Y11 receptors. ATP triggers a strong intracellular Ca2+ 
response. However, ATP is an agonist for the P2Y1, P2Y2, and P2Y11 receptors as well as for the P2X 
receptor family of ion channels which could all cause the observed rise of [Ca2+]i. As shown in Figure 
8A, the P2Y1 receptor-specific antagonist MRS2179 completely inhibits the Ca2+ response to ATP in 
HEK293 wildtype cells. Therefore, the Ca2+ response to ATP is entirely driven by the P2Y1 receptor 
and there is no contribution of other ATP-activated P2Y receptors. HEK293 wildtype cells show a Ca2+ 
response to UTP (Figure 8A). The P2Y2 receptor can be activated by UTP and ATP. However, P2Y2 
receptor activity can be ruled out, since the ATP-induced Ca2+ response was inhibited by MRS2179. 
Therefore, we suggest the presence of the UTP-preferring P2Y4 receptor in these cells. UDP did not 
induce an intracellular Ca2+ response, verifying the absence of P2Y6 receptor activity. 
 P2X1 and P2X7 receptors can be activated by BzATP with respective EC50 values in the nano- 
and micromolar range (Bianchi et al., 1999; Donnelly-Roberts et al., 2004). As no rise of [Ca2+]i was 
detected for BzATP concentrations of up to 100 µM (Figure 7), the expression of these receptors can 
be ruled out. 
In 1321N1 astrocytoma wildtype cells, the presence of the P2Y and P2X receptors, which 
could theoretically be the cause for a rise of [Ca2+]i, was ruled out, since all tested nucleotides were 
unable to induce a rise of [Ca2+]i (Figure 8B). 
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Figure 7: Concentration-response curves for the nucleotide-induced rise of [Ca2+]i in HEK293 
wildtype cells. Responses were induced using ATP, BzATP, or 2-MeS-ADP. The cells were pre-
incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) 
was detected, as described in methods. Numbers of experiments and cells are given in methods. 
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Figure 8: Amplitudes for the rise of [Ca2+]i in HEK293 wildtype cells and 1321N1 astrocytoma 
wildtype cells induced by different nucleotides. Responses were induced by ATP without or with 
the P2Y1 receptor-specific antagonist MRS2179, UTP, UDP, BzATP, and 2-MeS-ADP in A: HEK293 
wildtype cells and B: 1321N1 astrocytoma wildtype cells. The cells were pre-incubated with 2 µM 
Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, as 
described in methods. Numbers of experiments and analyzed cells are given in methods.  
 
Using confocal microscopy, the fluorescence intensities of GFP fused to the P2Y11, 
P2Y11A87T, P2Y11A87S, and P2Y11A87Y receptors in HEK293 cells were quantified in order to verify 
that the expression levels were equal. There was no statistical difference between fluorescence 
intensities of the GFP-tagged P2Y11, P2Y11A87T, and P2Y11A87S receptors (Figure 9). A small albeit 
significantly reduced fluorescence intensity of the GFP-tagged P2Y11A87Y receptor compared to the 
P2Y11 (P < 0.05) receptor was detected. 
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Figure 9: Fluorescence intensities of the P2Y11 receptors tagged with GFP expressed in 
HEK293 cells. Cells were expressing the P2Y11-GFP (n = 60), P2Y11A87T-GFP (n = 80), 
P2Y11A87S-GFP (n = 59), or P2Y11A87Y-GFP (n = 70) receptors (compare Figure 18). GFP 
fluorescence was detected via confocal microscopy with an excitation wavelength of 488 nm. 
* = significant difference (P < 0.05) of Ca2+ response amplitudes. 
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3.1.2 Investigation of nucleotide-induced cAMP accumulation in 1321N1 
astrocytoma and HEK293 cells expressing the wildtype P2Y11 or mutant 
P2Y11A87T receptor 
 
A unique feature of the P2Y11 receptor within the P2Y receptor family is the dual coupling to 
the Gq and Gs signaling pathways. Therefore, the ATP-induced elevation of intracellular cAMP levels 
in 1321N1 astrocytoma cells and HEK293 cells was compared between wildtype P2Y11 receptor and 
P2Y11A87T receptor. In 1321N1 astrocytoma wildtype cells, no cAMP generation was detected for 
ATP concentrations of up to 50 µM (Figure 10A). ATP equally induced cAMP generation in 1321N1 
astrocytoma cells expressing either the P2Y11 or the P2Y11A87T receptor. In HEK293 wildtype cells, 
no cAMP synthesis was detected for ATP concentrations of up to 100 µM (Figure 10B). In HEK293 
cells expressing the P2Y11A87T receptor and treated with 20 µM ATP a significantly (P < 0.05) 
reduced cAMP generation compared to cells expressing the P2Y11 receptor was found. 
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Figure 10: Levels of cAMP accumulation mediated by the P2Y11 or P2Y11A87T receptor induced 
by different concentrations of ATP. Data were obtained from A: 1321N1 astrocytoma cells and B: 
HEK293 cells. Wildtype cells (inset diagram) are compared to cells expressing the P2Y11 or 
P2Y11A87T receptor. The amount of cAMP per mg protein has been determined, as described in 
methods. * = significant difference (P < 0.05) of respective cAMP responses to 20 µM ATP of HEK293 
cells expressing the P2Y11 or the P2Y11A87T receptor. Numbers of experiments and analyzed cells are 
given in methods. 
 
3.1.3 Direct comparison of intracellular Ca2+ responses of transfected and non-
transfected HEK293 cells under identical experimental conditions  
 
GFP fluorescence of labeled P2Y receptors is used in the experiments to identify transfected 
cells within a cell culture. For the determination of EC50 values, nucleotide-induced Ca2+ response 
amplitudes only from GFP-fluorescent cells were included in the analysis, as described before, and 
non-fluorescent cells were ignored. However, usually about 50% of cells within a cell culture do not 
show GFP fluorescence. These cells do not express the P2Y receptor of interest. This offers the 
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opportunity to measure intracellular Ca2+ responses of P2Y receptor-expressing cells (GFP-positive) 
and non-transfected (GFP-negative) wildtype cells under identical experimental conditions (Figure 11). 
Ca2+ responses were evoked by BzATP, 2-MeS-ADP, or ATP in HEK P2Y11 receptor and 
HEK P2Y11A87T receptor cell cultures. Additionally, the response to ATP was analyzed without and 
with the addition of the P2Y1 receptor antagonist MRS2179 (Table 3). For our analysis, the factor “F” 
was introduced. “F” is defined as the ratio of the nucleotide-induced Ca2+ response amplitude of GFP-
positive cells divided by the response amplitude of GFP-negative cells. F > 1 shows that the Ca2+ 
response of GFP-positive cells was higher than that of GFP-negative cells, while F < 1 indicates a 
lower response of GFP-positive cells. 
 Treatment of HEK293 cells expressing the P2Y11 receptor with 3 µM BzATP lead to a 
9.5-times higher Ca2+ response amplitude than in GFP-negative cells at the same time (P < 0.01; 
Figure 12A), meaning that F = 9.5 (Table 3). The addition of 10 µM BzATP lead to a similar result with 
F = 9.0 (P < 0.01). This is consistent with our earlier finding that the Ca2+ response to BzATP in 
HEK293 cells expressing the P2Y11 receptor is already near-maximal at a nucleotide concentration of 
3 µM (compare Figure 4B). In cultures containing P2Y11A87T receptor-expressing cells, 3 µM and 10 
µM BzATP lead to a negligible Ca2+ response in GFP-positive cells, which was similar to that in GFP-
negative cells. 
 Challenge of cell cultures containing P2Y11 receptor-expressing cells with 1 µM or 3 µM 
2-MeS-ADP lead to a reduced Ca2+ response (P < 0.01; Figure 12A) in GFP-positive cells with F = 0.6 
and F = 0.8, respectively (Table 3). In cell cultures containing P2Y11A87T receptor-expressing cells, 
the decrease (P < 0.01; Figure 12A) was even stronger with F = 0.3 for both concentrations of 
2-MeS-ADP.  
 In agreement with our earlier results (Figure 6B; Figure 7), HEK293 cells expressing the 
P2Y11A87T receptor show a significantly (P < 0.01; Figure 12B) decreased Ca2+ response to 3 µM 
ATP, as compared to non-transfected cells (F = 0.6), while HEK293 cells expressing the P2Y11 
receptor show a slightly but significantly increased (P < 0.05; Figure 12B) Ca2+ response (F = 1.3). 
The addition of the antagonist MRS2179 (100 µM) abolished the intracellular Ca2+ response to 3 µM 
ATP of GFP-negative cells. Interestingly, while the P2Y1 receptor antagonist inhibited ATP-induced 
Ca2+ responses in P2Y11A87T receptor expressing cells, GFP-positive cells in HEK P2Y11 cell cultures 
were not affected. 
 10 µM ATP lead to Ca2+ response amplitudes, which were comparable to those evoked by 
3 µM ATP with F = 1.2 for cultures containing P2Y11 receptor-expressing cells and F = 0.6 for cultures 
containing P2Y11A87T receptor expressing cells. 
GFP-negative HEK293 cells of all tested cultures showed Ca2+ responses to BzATP, 
2-MeS-ADP, and ATP, which were similar to the responses of HEK293 wildtype cells measured in a 
separate culture (Table 3). This confirmed the non-transfected state of the GFP-negative cells. 
HEK293 cells expressing the P2Y11A87T receptor displayed equal or lower Ca2+ response amplitudes 
than the corresponding GFP-negative cells in all measurements. We attribute this characteristics to 
the interaction of the P2Y11A87T receptors with the P2Y1 receptors in these cells. 
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Figure 11: Examples of intracellular Ca2+ measurements with a HEK293 cell culture 
containing P2Y11A87T receptor-expressing (GFP+) cells and non-transfected (GFP-) 
cells. Responses were induced using 2-MeS-ADP (1 µM; black arrowheads). A: Traces of the 
Ca2+ response of cells expressing the P2Y11A87T receptor (GFP+).  
B: Traces of the Ca2+ response of non-transfected cells (GFP-).  
 
 
 
Fura-2 fluorescence of all cells 
C/D: Fluorescence microscopy with cells used in 
A and B. Red asterisks: GFP+ cells 
(corresponding to Ca2+ responses shown in A). 
Orange outlines: GFP- cells (corresponding to 
Ca2+ responses shown in B) C: All HEK293 cells 
analyzed in this experiment visualized by Fura-2 
fluorescence (380 nm excitation). D: GFP 
fluorescence (480 nm excitation) of HEK293 cells 
expressing the P2Y11A87T receptor. For the Ca2+ 
measurements, the cells were pre-incubated with 
2 µM Fura-2 AM for 30 min and the change in 
fluorescence (F340 nm / F380 nm) was detected, 
as described in methods. 
 
 
  
 
GFP-fluorescence  
of the P2Y11A87T receptor-expressing 
cells 
 
    
 
C 
D 
3. Results 
 37 
 
Table 3: Amplitudes of Ca2+ responses in HEK293 cell cultures of GFP-positive (GFP+) cells 
expressing the P2Y11 or P2Y11A87T receptor and non-transfected, GFP-negative (GFP-) cells. 
Responses were induced using BzATP, 2-MeS-ADP, ATP, and ATP in combination with the P2Y1 
receptor antagonist MRS2179 (compare Figure 12). The cells were pre-incubated with 2 µM Fura-2 
AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, as described in 
methods. If required, MRS2179 was added to the buffer 30 min prior to the measurement and used 
together with ATP. For data comparison, the factor “F” of the Ca2+ response amplitudes of GFP-
positive / GFP-negative cells is given. F > 1.0 (green numbers) means that GFP+ cells showed higher 
response amplitudes than GFP- cells. F ≤ 1.0 (red numbers) means that GFP+ cells showed equal 
lower response amplitudes than GFP- cells. 
 
Intracellular Ca2+ response amplitudes 
 
Δ (F340 nm / F380 nm) +/- SEM 
  P2Y11  P2Y11A87T  Control:
HEK293 
wildtype  Nucleotide  GFP - GFP + F  GFP - GFP + F  
BzATP (3 µM)  
0.2 
+/- 0.02 
1.9 
+/- 0.07 
9.5  
0.09 
+/- 0.02 
0.09 
+/- 0.02 
1.0  
0.07 
+/- 0.01 
BzATP (10 µM)  
0.2 
+/- 0.01 
1.8 
+/- 0.1 
9.0  
0.2 
+/- 0.04 
0.07 
+/- 0.01 
0.4  
0.07 
+/- 0.003 
2-MeS-ADP (1 µM)  
1.9 
+/- 0.06 
1.1 
+/- 0.1 
0.6  
1.5 
+/- 0.1 
0.5 
+/- 0.08 
0.3  
2.1 
+/- 0.06 
2-MeS-ADP (3 µM)  
3.0 
+/- 0.1 
2.5 
+/- 0.1 
0.8  
2.6 
+/- 0.15 
0.8 
+/- 0.03 
0.3  
2.5 
+/- 0.06 
ATP (3 µM)  
1.6 
+/- 0.07 
2.0 
+/- 0.07 
1.3  
1.9 
+/- 0.08 
1.2 
+/- 0.06 
0.6  
1.8 
+/- 0.05 
ATP (3 µM) + 
MRS2179 (100 µM) 
 
0.4 
+/- 0.07 
1.9 
+/- 0.1 
4.8  
0.2 
+/- 0.04 
0.1 
+/- 0.01 
0.5  
0.2 
+/- 0.03 
ATP (10 µM)  
1.8 
+/- 0.06 
2.2 
+/- 0.11 
1.2  
2.5 
+/- 0.06 
1.6 
+/- 0.05 
0.6  
2.2 
+/- 0.06 
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Figure 12: Amplitudes of Ca2+ responses of GFP-positive (GFP+) cells expressing the P2Y11 or 
P2Y11A87T receptor and non-transfected, GFP-negative (GFP-) cells in HEK293 cell cultures. 
Responses were induced using A: BzATP, 2-MeS-ADP, and B: ATP without or in combination with 
the P2Y1 receptor antagonist MRS2179. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min 
and the change in fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. If 
required, MRS2179 was added to the buffer 30 min prior to the measurement and used together with 
ATP. **/ * = significant difference (P < 0.01; P < 0.05, respectively) of Ca2+ response amplitudes. 
Numbers of experiments and analyzed cells are given in methods. 
 
In order to rule out the possibility that it is merely the GFP-tag fused to the P2Y11 or 
P2Y11A87T receptor, which causes the observed changes in nucleotide-induced intracellular Ca2+ 
responses, the following experiment was conducted. GFP-negative HEK293 cells and cells expressing 
the Gq coupled protease-activated receptor (PAR) 2 with a C-terminal GFP-tag (Table 4) were 
challenged with ATP concentrations of 3 µM and 10 µM. Both concentrations of ATP evoked identical 
Ca2+ response amplitudes in GFP-positive and GFP-negative HEK293 cells. Thus, the GFP-tag fused 
to the P2Y11 or P2Y11A87T receptors did not influence the measurements.  
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Table 4: Amplitudes of Ca2+ responses in HEK293 cell cultures of GFP-positive (GFP+) cells 
expressing the protease-activated receptor (PAR) 2 and non-transfected, GFP-negative (GFP-) 
cells. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence 
(Δ F340 nm / F380 nm) was detected, as described in methods.  
 
Intracellular Ca2+ response amplitudes 
 
Δ (F340 nm / F380 nm) +/- SEM 
  PAR 2 Control: 
HEK293 wildtype Nucleotide  GFP - GFP + 
ATP (3 µM)  
1.5 
(+/- 0.05) 
1.4 
(+/- 0.04) 
1.8 
+/- 0.05 
ATP (10 µM)  
2.0 
(+/- 0.08) 
2.0 
(+/- 0.06) 
2.2 
+/- 0.06 
 
3.1.4 Co-expression of the P2Y11 or P2Y11A87T receptor with the P2Y1 receptor 
in 1321N1 astrocytoma cells 
 
Differences in the Ca2+ responses mediated by the P2Y11A87T and P2Y11 receptor were found 
only in HEK293 cells, but not in 1321N1 astrocytoma cells. HEK293 cells endogenously express the 
P2Y1 receptor, but 1321N1 astrocytoma cells lack any endogenous P2Y receptor expression. In order 
to investigate whether the presence of the P2Y1 receptor is necessary for reduced Ca2+ responses 
mediated by P2Y11A87T receptor, the P2Y11A87T or P2Y11 receptors were co-expressed with the 
P2Y1 receptor in 1321N1 astrocytoma cells (Figure 13). The results were compared to 1321N1 
astrocytoma wildtype cells and cells expressing the P2Y11 or P2Y11A87T receptor alone.  
The intracellular Ca2+ concentration of the 1321N1 astrocytoma cells was monitored during 
treatment with 1 µM of the P2Y11 receptor agonist BzATP and, after a recovery period of at least 2 
min, a subsequent treatment with 1 µM of the potent P2Y1 receptor agonist 2-MeS-ADP. 1321N1 
astrocytoma cells expressing the P2Y11 or P2Y11A87T receptor showed clear GFP fluorescence. A 
response to 2-MeS-ADP verified functional P2Y1 receptor expression. Fluorescence traces showing 
the Ca2+ mobilization in representative experiments with 1321N1 astrocytoma cells co-expressing the 
P2Y1 with P2Y11 or P2Y11A87T receptors and cells expressing the P2Y11A87T receptor alone are 
presented in Figure 14.  
Single-transfected 1321N1 astrocytoma cells expressing only the P2Y1 receptor showed a 
negligible Ca2+ response to BzATP, but a strong response to 2-MeS-ADP (Figure 13). Single-
transfected cells expressing the P2Y11 or P2Y11A87T receptor showed a strong Ca2+ response to 
BzATP (no statistically significant difference) and no Ca2+ response to 2-MeS-ADP. Cells co-
expressing the P2Y11 with the P2Y1 receptor showed a Ca2+ response amplitude to the BzATP 
stimulus, similar to that of the single-transfected P2Y11 or P2Y11A87T receptor-expressing cells.  
 Only in 1321N1 astrocytoma cells co-expressing the P2Y11A87T with the P2Y1 receptor, there 
was a significantly reduced Ca2+ response to BzATP, compared to cells co-expressing the P2Y11 with 
P2Y1 receptor (P < 0.01; Figure 13). Also, the respective responses to BzATP of the cells co-
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expressing the P2Y11A87T and P2Y1 receptor was significantly lower than that of cells expressing the 
P2Y11A87T receptor (P < 0.01) or the P2Y11 receptor (P < 0.01) alone. The Ca2+ responses to 2-MeS-
ADP of all single- or double-transfected cells with P2Y1 receptor expression were similar. 
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Figure 13: Amplitudes of the rise of [Ca2+]i in 1321N1 astrocytoma cells co-expressing the P2Y1 
and P2Y11 or P2Y11A87T receptors, respectively. Response amplitudes were compared with cells 
expressing the P2Y1, P2Y11, or P2Y11A87T receptors alone. Cells were treated sequentially with a 
1 min-pulse of BzATP (1 µM) followed by a 1 min-pulse of 2-MeS-ADP (1 µM) after an intermittent 
recovery period of at least 2 min. This stimulus pattern is given above the bar diagram. The cells were 
pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) 
was detected, as described in methods. **/ * = significant differences (P < 0.01 and P < 0.05, 
respectively) of Ca2+ response amplitudes. Dashed line represents background response of 1321N1 
wildtype cells to the BzATP treatment. Numbers of experiments and analyzed cells are given in 
methods.  
 
 
 
 
 
Major conclusions 
 
Only P2Y11A87T and P2Y1 receptor co-expressing cells show reduced Ca2+ 
response to BzATP. 
 
P2Y11 and P2Y1 receptor co-expressing cells and P2Y11 and P2Y11A87T 
receptor single-expressing cells show comparable Ca2+ response to BzATP. 
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Figure 14: Representative traces for intracellular Ca2+ mobilization in single- and double-
transfected 1321N1 astrocytoma cells. Responses were induced in cells expressing A: the P2Y1 
and P2Y11A87T receptors, B: the P2Y11A87T receptor alone, and C: the P2Y1 and P2Y11 receptors. 
Cells were treated sequentially with a 1 min-pulse of BzATP (1 µM) followed by a 1 min-pulse of 
2-MeS-ADP (1 µM) after an intermittent recovery period of circa 3 min (A/B) or 2 min (C). The cells 
were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence 
(Δ F340 nm / F380 nm) was detected, as described in methods. 
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As can be seen in Figure 15, the P2Y1-myc/His, P2Y11-GFP, and P2Y11A87T-GFP proteins 
were found to be localized at the plasma membrane in the 1321N1 astrocytoma cells. There was no 
statistical difference in receptor expression levels according to the GFP and Alexa555 fluorescence 
levels Figure 16. 
The rise of the intracellular Ca2+ level mediated by the P2Y1-myc/His receptor expressed in 
1321N1 astrocytoma cells was similar to the response mediated by the P2Y1-GFP receptor for 
concentrations of 2-MeS-ADP of 0.001 µM, 0.01 µM, and 1.0 µM (Figure 17). Only at a concentration 
of 2-MeS-ADP of 0.001 µM, the P2Y1-myc/His receptor showed a higher response amplitude 
(P < 0.05). Furthermore, the P2Y1-myc/His receptor has been shown before to undergo nucleotide-
induced endocytosis in 1321N1 astrocytoma cells, like the P2Y1-GFP receptor (Ecke et al., 2008a). 
This demonstrates identical functioning of P2Y1 receptors with both tags. This is in line with an earlier 
study (Tulapurkar et al., 2005) in which the rat P2Y2-GFP and P2Y2-myc/His receptor were compared 
regarding the nucleotide-induced intracellular Ca2+ elevation and were found to respond very similarly. 
 
P2Y1-myc/His 
+ 
P2Y11-GFP 
   
P2Y1-myc/His 
+ 
P2Y11A87T-
GFP 
   
 GFP A555 merge 
 
Figure 15: Co-expression of the P2Y1-myc/His and P2Y11-GFP or P2Y11A87T-GFP receptors in 
1321N1 astrocytoma cells. Cells were fixed with para-formaldehyde and GFP-fluorescence (green) 
was visualized with 488 nm excitation. The P2Y1-myc/His receptors (red) were detected via 
α-mycA555 antibody binding and excitation at 543 nm. Immunocytochemistry was performed, as 
described in methods. 
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Figure 16: Fluorescence intensities of GFP and Alexa555 in 1321N1 astrocytoma cells 
co-expressing the P2Y1-myc/His and P2Y11-GFP (n = 75) or P2Y11A87T-GFP receptors (n = 46). 
GFP-fluorescence was visualized with 488 nm excitation. Alexa555 was detected via α-mycA555 
antibody binding and excitation at 543 nm (compare Figure 15). Immunocytochemistry was performed, 
as described in methods. 
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Figure 17: Amplitudes of the rise of [Ca2+]i in 1321N1 astrocytoma cells expressing the human 
P2Y1-GFP or P2Y1-myc/His receptors. Responses were induced using different concentrations of 
2-MeS-ADP. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in 
fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of experiments 
and analyzed cells are given in methods. * = significant difference (P < 0.05) of the Ca2+ responses to 
0.001 µM 2-MeS-ADP. 
 
3.1.5 Long-term treatment of HEK293 cells with nucleotides: receptor 
internalization of P2Y11A87T, P2Y11A87S, and P2Y11A87Y receptors and long-
term Ca2+ response sensitization 
 
Wildtype P2Y11 receptors expressed in HEK293 cells undergo nucleotide-induced 
internalization (Ecke et al., 2008). Therefore, the nucleotide-induced change of the localization of the 
GFP-labeled P2Y11, P2Y11A87T, P2Y11A87S, and P2Y11A87Y receptors in HEK293 cells was 
analyzed using confocal microscopy (Figure 18). 100 µM ATP or 100 µM BzATP were applied for 
60 min. Untreated control cells showed plasma membrane localization of GFP fluorescence. In the 
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P2Y11 receptor-expressing cells, ATP and BzATP caused a strong receptor internalization, as 
indicated by the accumulation of spots of GFP fluorescence in the cytosol. However, no nucleotide-
induced internalization was detected in cells expressing the P2Y11A87T or P2Y11A87Y receptor. In 
cells expressing the P2Y11A87S receptor, treatment with ATP lead to a slight receptor internalization 
and with BzATP to a clear internalization of GFP-labeled receptors.  
 
Nucleotides 
Receptor 
P2Y11 P2Y11A87T P2Y11A87S P2Y11A87Y 
None 
    
ATP 
(100 µM) 
    
BzATP 
(100 µM) 
    
 
Figure 18: Nucleotide-induced internalization of wildtype P2Y11 and mutated P2Y11 receptors in 
HEK293 cells. Localization of GFP fluorescence of the P2Y11, P2Y11A87T, P2Y11A87S, and 
P2Y11A87Y receptors expressed as GFP fusion proteins in HEK293 cells. Representative pictures 
were taken after treatment with ATP or BzATP for 60 min, or without nucleotide treatment and fixation 
of the cells with para-formaldehyde. Scale bar represents 10 µm. White arrowheads indicate GFP 
fluorescence of internalized P2Y11 or P2Y11A87S receptors.  
 
 The lack of receptor internalization after extended treatment with a high concentration of ATP 
indicates that the prominent detrimental effect of the A87T mutation of the P2Y11 receptor is most 
likely connected to the long-term regulation of intracellular Ca2+ signaling. Thus, it was investigated 
whether the lack of receptor internalization in HEK293 cells expressing the P2Y11A87T receptor would 
result in an overall higher responsiveness of cells after a prolonged treatment with ATP. For this, cells 
were incubated with 100 µM ATP for 30 min, which is sufficient to induce receptor internalization in 
P2Y11 receptor-expressing cells, and the change of intracellular Ca2+ concentration was monitored 
(Figure 19). After 30 min, ATP was replaced with nucleotide-free buffer and the cells were superfused 
for 60 min to allow for cell recovery. Finally, a short 1 min treatment with ATP (100 µM) was used to 
determine the extent of cell responsiveness after 90 min. This gives the long-term sensitivity of cells 
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co-expressing the P2Y1 with P2Y11, P2Y11A87T, or P2Y11A87S receptors. In Figure 20A, the first bar 
represents the initial Ca2+ response amplitude to ATP (100 µM). The second bar indicates the 
remaining level of Ca2+i after 30 min incubation with ATP (100 µM), and the third bar shows the Ca2+ 
response to the second short treatment with ATP (100 µM). Compared with HEK293 cells expressing 
the wildtype P2Y11 receptor, cells expressing the mutated P2Y11 receptors showed stronger 
desensitization of the Ca2+ response after 30 min, which was coupled with stronger resensitization 
after 90 min. 
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Figure 19: Traces of ATP-induced long-term intracellular Ca2+ mobilization in HEK293 cells 
expressing the P2Y11A87T receptor. Non-normalized, exemplary data from cells of a single 
experiment are shown. Cells were incubated with ATP for 30 min followed by a 60 min superfusion 
with nucleotide-free NaHBS buffer for recovery. Finally, a short 1 min ATP stimulus was applied. The 
cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in fluorescence 
(F340 nm / F380 nm) was detected, as described in methods. 
 
For HEK293 cells expressing the P2Y11 receptor, we detected a significantly reduced 
(P < 0.01) Ca2+ level after 30 min continuous ATP-treatment down to 25% of the initial response. After 
the following 30 min superfusion with nucleotide-free buffer (at a total of 90 min), the intracellular Ca2+ 
response increased only 1.4-fold to 34% of the response at 0 min (P < 0.01). In HEK293 cells 
expressing the P2Y11A87T receptor, 30 min treatment with ATP reduced the [Ca2+]i to 15% of the 
response at 0 min (P < 0.01). The extent of the response desensitization therefore was significantly 
higher (P < 0.01) than in cells expressing the P2Y11 receptor. At 90 min, the Ca2+ response was 
restored with a factor of 3.4 (P < 0.01) as compared to the Ca2+ level at 30 min. It thus reached 51% of 
the response at 0 min. Recovery of the Ca2+ response of HEK293 cells expressing the P2Y11A87T 
receptor therefore was higher than that of P2Y11 receptor-expressing cells. The Ca2+ response after 
30 min continuous ATP-treatment in HEK293 cells expressing the P2Y11A87S receptor was reduced 
to 12% of the initial response at 0 min (P < 0.01). The response at 90 min was increased significantly 
(P < 0.01) to 4.8-fold of the response at 30 min, reaching 57% of the initial response at 0 min. Thus, 
desensitization and recovery of the intracellular Ca2+ response of HEK293 cells expressing the 
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P2Y11A87S receptor was comparable to what had been observed for P2Y11A87T receptor expressing 
cells.  
 A technical control experiment using HEK293 wildtype cells was conducted in order to rule out 
that stress due to the extended single-cell Ca2+ measurements could have caused non-physiological 
Ca2+ levels in the cells (Figure 20B). Cells superfused with NaHBS buffer for 90 min prior to a 1 min 
treatment with 100 µM ATP showed the same Ca2+ response amplitude like cells that were not 
pretreated. This confirms that the observed changes of intracellular Ca2+ responses of the HEK293 
cells were not falsified by the experimental conditions. 
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Figure 20: Nucleotide-induced long-term desensitization of Ca2+ responses in HEK293 cells 
expressing the wildtype P2Y11, P2Y11A87T, or P2Y11A87S receptor. A: Amplitudes of the rise of 
[Ca2+]i in HEK293 cells expressing the P2Y11, P2Y11A87T, or P2Y11A87S receptors. Cells were 
incubated with ATP for 30 min followed by a 60 min superfusion with nucleotide-free Na-HBS buffer 
for recovery. Finally, a short 1 min ATP stimulus was applied. B: Amplitudes of the rise of [Ca2+]i in 
HEK293 wildtype cells induced by ATP with and without preceding 90 min superfusion with nucleotide-
free Na-HBS buffer. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in 
fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. 
** = significant differences (P < 0.01) of Ca2+ response amplitudes. n.s. = no significant differences of 
Ca2+ response amplitudes. Numbers of experiments and analyzed cells are given in methods. 
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3.2 Potency of 2-propylthio-substituted derivatives of ATP on 1321N1 
astrocytoma cells expressing the human P2Y1, P2Y2, or P2Y11 receptors 
3.2.1 Investigation of nucleotide potencies at the human P2Y11 receptor 
expressed in 1321N1 astrocytoma cells 
 
 For the investigation of the potencies of the novel ATP analogs (Figure 21), single-cell Ca2+ 
measurements were conducted on the human P2Y11 receptor expressed in 1321N1 astrocytoma cells. 
Following the structural features of one of the most potent agonists of the P2Y11 receptor, 
2-propylthio-ATP-β,γ-dichloromethylene (AR-C67085), a series of 2-propylthio-substituted derivatives 
of ATP was generated. The novel analogs contained a 2-propylthio modification in combination with a 
β,γ-CCl2 group and/or a Pα substitution of a non-bridging oxygen. The introduction of the Pα-BH3 or 
Pα-S substitutions created a new chiral center at this position. As described in Haas et al., 2013, the 
Rp configuration was assigned to the A-isomers of borano-substituted nucleotides and to the B-
isomers of thio-substituted nucleotides. The Sp configuration therefore was assigned to the B-isomers 
of the borano- and to the A-isomers of the thio-substituted analogs. The resulting isomers were 
investigated separately. 
  
nucleotide  substitutions 
2-propylthio-ATP-αS (A/B)  Y = S Z = O X = O 
2-propylthio-ATP-αB (A/B)  Y = O Z = BH3 X = O 
2-propylthio-ATP-αS-β,γ-CCl2 (A/B)  Y = S Z = O X = CCl2 
2-propylthio-ATP-αB-β,γ-CCl2 (A/B)  Y = O Z = BH3 X = CCl2 
2-propylthio-ATP  Y = O Z = O X = O 
 
Figure 21: Structure of 2-propylthio-substituted nucleotide derivatives of ATP used for the 
investigation of potency and selectivity at the P2Y11 receptor (modified from Haas et al., 2013). 
 
The well-known diastereoselectivity of the human P2Y11 receptor (Ecke et al., 2008b) could 
not be observed for the isomers of 2-propylthio-ATP-αS, since the concentration-response curves 
were not significantly different (Figure 22A). The EC50 values at the P2Y11 receptor were very similar 
with 0.22 +/- 0.04 µM for the A-isomer and 0.19 +/- 0.06 µM for the B-isomer of the analog (Table 5). 
Nevertheless, both nucleotides showed a more than 10-times higher potency at the P2Y11 receptor 
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than the physiological standard agonist ATP (EC50 = 2.6 +/- 0.6 µM). The isomers of ATP-αS were 
previously shown to activate the P2Y11 receptor with very different potencies (Ecke et al., 2006). 
Therefore, the 2-propylthio-substitution of the 2-propylthio-ATP-αS analogs is responsible for 
abolishing the stereospecificity in the activation of the P2Y11 receptor. 
 The structurally similar 2-propylthio-ATP-αB, carrying  an α-borano substitution instead of the 
α-thio group, however, displays a clear and significant P2Y11 receptor preference for the B-isomer over 
the A-isomer (Figure 22B). The EC50 value for the B-isomer was at 0.03 +/- 0.01 µM while the EC50 
value for the A-isomer was at 0.40 +/- 0.05 µM (Table 5). This makes the B-isomer about 13-fold more 
potent than the A-isomer. Both isomers yielded lower EC50 values than ATP. However, while the A-
isomer was only about 7-fold more potent, the B-isomer was 87-times more effective than ATP in 
evoking intracellular Ca2+ responses. Also, the diastereoselectivity at the P2Y11 receptor of the tested 
nucleotides was greatest for the isomers of 2-propylthio-ATP-αB. 
 Like AR-C67085, 2-propylthio-ATP-αS-β,γ-CCl2 possesses a dichloromethylene group 
between the β- and γ-phosphate but otherwise resembles the analogs used in Figure 22A. The 
isomers of the α-thio substituted nucleotide show no prominent diastereoselectivity at the P2Y11 
receptor (Figure 22C) as the EC50 value for the A-isomer was at 0.6 +/- 0.03 µM and for the B-isomer 
at similar 0.85 +/- 0.2 µM (Table 5). Thus, the B-isomer was about 3-fold more potent and the A-
isomer about 4-fold more potent than ATP. 
2-propylthio-ATP-αB-β,γ-CCl2 corresponds to the nucleotides used in Figure 22C but features 
an α-borano group instead of the α-thio group. Again, the α-BH3 substitution restores significant 
stereoselectivity at the P2Y11 receptor of the 2-propylthio-ATP derivative compared to the α-thio 
substituted compound (Figure 22D). The EC50 value for the B-isomer was at 0.03 +/- 0.01 µM and for 
the A-isomer at 0.1 +/- 0.05 µM (Table 5). Thus, the B-isomer was only circa 3-fold more potent than 
the A-isomer and diastereoselectivity was less pronounced than for 2-propylthio-ATP-αB. Since the B-
isomers of 2-propylthio-ATP-αB and 2-propylthio-ATP-αB-β,γ-CCl2 share the same EC50 value of 
0.03 µM, the latter also is around 87-fold more potent than ATP.  
The potency of 2-propylthio-ATP was shown to be virtually identical to that of ATP. The EC50 
values of 2.5 +/- 0.5 µM for 2-propylthio-ATP and 2.6 +/- 0.6 µM for ATP were very similar (Table 5). 
Differences in the concentration-response curves were non-significant (Figure 22E). Therefore, the 
propylthio-substitution at position 2 of the adenine alone cannot account for an increased potency of 
the aforementioned nucleotides as compared to that of ATP. 
The rank order of potencies for the tested novel adenine nucleotides was found to be:  
2-propylthio-ATP-αB(B) = 2-propylthio-ATP-αB-β,γ-CCl2(B) >> 2-propylthio-ATP-αB-β,γ-CCl2(A) =  
2-propylthio-ATP-αS(B) = 2-propylthio-ATP-αS(A) > 2-propylthio-ATP-αB(A) >  
2-propylthio-ATP-αS-β,γ-CCl2(A) > 2-propylthio-ATP-αS-β,γ-CCl2(B) >> 2-propylthio-ATP = ATP. 
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Figure 22: Concentration-response curves for the rise of [Ca2+]i induced by 2-propylthio-
substituted analogs of ATP in 1321N1 astrocytoma cells expressing the human P2Y11 receptor. 
Responses were induced by A: 2-propylthio-ATP-αS (A/B), B: 2-propylthio-ATP-αB (A/B),  
C: 2-propylthio-ATP-αS-β,γ-CCl2 (A/B), D: 2-propylthio-ATP-αB-β,γ-CCl2 (A/B), E: ATP, and 2-
propylthio-ATP. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in 
fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of experiments 
and analyzed cells are given in methods. B: ** = significant differences (P < 0.01) of Ca2+ response 
amplitudes to 0.1 µM of the A-isomer and 0.1 µM and 0.03 µM of the B-isomer of the nucleotide; 
## = significant difference (P < 0.01) of Ca2+ response amplitudes to 0.5 µM of the A-isomer and 
0.1 µM of the B-isomer of the nucleotide. C/D: ** = significant differences (P < 0.01) of Ca2+ response 
amplitudes to the respective concentrations of nucleotides. 
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Table 5: Potencies (EC50 values in µM) of ATP and novel 2-propylthio-substituted analogs of 
ATP at the human P2Y11 receptor expressed in 1321N1 astrocytoma cells. Data were derived 
from concentration-response curves given in Figure 22. 
 
Nucleotide  
Intracellular Ca2+ response 
EC50 (µM) +/- SEM 
2-propylthio-ATP-αS (A-isomer, Sp)  0.22 +/- 0.04 (Fig. 22A) 
2-propylthio-ATP-αS (B-isomer, Rp)  0.19 +/- 0.06 (Fig. 22A) 
2-propylthio-ATP-αB (A-isomer, Rp)  0.40 +/- 0.05 (Fig. 22B) 
2-propylthio-ATP-αB (B-isomer, Sp)  0.03 +/- 0.01 (Fig. 22B) 
2-propylthio-ATP-αS-β,γ-CCl2 (A-isomer, Sp)  0.6 +/- 0.03 (Fig. 22C) 
2-propylthio-ATP-αS-β,γ-CCl2 (B-isomer, Rp)  0.85 +/- 0.2 (Fig. 22C) 
2-propylthio-ATP-αB-β,γ-CCl2 (A-isomer, Rp)  0.1 +/- 0.05 (Fig. 22D) 
2-propylthio-ATP-αB-β,γ-CCl2 (B-isomer, Sp)  0.03 +/- 0.01 (Fig. 22D) 
2-propylthio-ATP  2.5 +/- 0.5 (Fig. 22E) 
ATP  2.6 +/- 0.6 (Fig. 22E) 
 
 
 
Major conclusion 
 
Sp-2-propylthio-ATP-αB and Sp-2-propylthio-ATP-αB-β,γ-CCl2 
are the most potent of the tested P2Y11 receptor agonists. 
 
3.2.2 Investigation of nucleotide specificity for the P2Y11 over the P2Y1 and 
P2Y2 receptors expressed in 1321N1 astrocytoma cells 
 
 Adenine nucleotides can trigger intracellular Ca2+ responses not only due to agonistic activity 
at the P2Y11 receptor, but also by activating the P2Y1 or P2Y2 receptors. To verify nucleotide specificity 
for the P2Y11 receptor, the novel 2-propylthio-ATP derivatives therefore were tested on 1321N1 
astrocytoma cells expressing P2Y1 or P2Y2 receptors (Figure 23). Response amplitudes to 10 µM of 
the tested nucleotides at the P2Y11 receptor are given in Figure 23A for comparison. 
 At the P2Y1 receptor, only the B-isomer of 2-propylthio-ATP-αS-β,γ-CCl2 and the A-isomer of 
2-propylthio-ATP-αB-β,γ-CCl2 (10 µM each) did not trigger a rise of [Ca2+]i (Figure 23B). The 
nucleotides, which showed the highest potency at the P2Y11 receptor were the B-isomers of 
2-propylthio-ATP-αB-β,γ-CCl2 and 2-propylthio-ATP-αB (EC50 values = 0.03 µM). At the P2Y1 receptor 
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the latter analog triggered a response of about 44% of that of ATP. Since the response to 
2-propylthio-ATP-αB-β,γ-CCl2(B) was only about 22% of that of ATP, this nucleotide shows better 
specificity for the P2Y11 receptor over the P2Y1 receptor. For 2-propylthio-ATP, an EC50 value of 0.04 
+/- 0.01 µM was obtained at the P2Y1 receptor (Figure 24). For the other nucleotide derivates, a clear 
plateau of the intracellular Ca2+ response could not be reached for concentrations of up to 10 µM. 
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Figure 23: Amplitudes of the rise of [Ca2+]i induced by the novel 2-propylthio-substituted 
analogs of ATP in 1321N1 astrocytoma cells expressing the P2Y11, P2Y1, or P2Y2 receptor. 
Ca2+ responses were induced using ATP, UTP, 2-propylthio-ATP-αS (A/B), 2-propylthio-ATP-αB (A/B), 
2-propylthio-ATP-αS-β,γ-CCl2 (A/B), 2-propylthio-ATP-αB-β,γ-CCl2 (A/B), and 2-propylthio-ATP in cells 
expressing the A: P2Y11 receptor, B: P2Y1 receptor, C: P2Y2 receptor, or D: 1321N1 astrocytoma 
wildtype cells. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the change in 
fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of experiments 
and analyzed cells are given in methods. **/ * = significant differences (P < 0.01; P < 0.05, 
respectively) of Ca2+ response amplitudes to ATP and the tested nucleotide derivatives. 
## = significant differences (P < 0.01) of Ca2+ response amplitudes to UTP and the tested nucleotide 
derivatives. 
3. Results 
 52 
 At the P2Y2 receptor, only a concentration of 10 µM of 2-propylthio-ATP evoked a notable 
response (Figure 23C). A plateau of the intracellular Ca2+ response could, however, not be reached. 
The response to the other nucleotide derivatives did not exceed baseline or was minimal.  
 None of the tested nucleotides, including the physiological nucleotides UTP and ATP, evoked 
an intracellular Ca2+ response in 1321N1 astrocytoma wildtype cells for a concentration of 10 µM 
(Figure 23D). 
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Figure 24: Concentration-response curve for the rise of [Ca2+]i in 1321N1 astrocytoma cells 
expressing the human P2Y1 receptor induced by 2-propylthio-ATP. The cells were pre-incubated 
with 2 µM Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, 
as described in methods. Numbers of experiments and analyzed cells are given in methods. 
 
3.2.3 Investigation of cAMP accumulation induced by the 2-propylthio-ATPαB 
analogs in 1321N1 astrocytoma cells expressing the human P2Y11 receptor 
 
 The P2Y11 receptor is dually coupled to the Gq and Gs signaling pathways. Therefore, the 
nucleotides with the lowest EC50 value for the induction of the Gq pathway were tested whether they 
activate the adenylyl cyclase in 1321N1 astrocytoma cells expressing the human P2Y11 receptor 
(Figure 25). The B-isomers of 2-propylthio-ATP-αB and 2-propylthio-ATP-αB-β,γ-CCl2 were tested at 
concentrations of 0.01 to 10 µM and achieved a comparable accumulation of intracellular cAMP. The 
half-maximal concentrations were approximately 0.1 µM. This corresponds to the EC50 values of both 
nucleotides of 0.03 µM for the rise of [Ca2+]i at the P2Y11 receptor.  
 In order to analyze, whether the specificity of the P2Y11 receptor for the B-isomers of the 
nucleotide derivatives can be detected for the induction of the Gs pathway as well, we additionally 
tested the A-isomer of 2-propylthio-ATP-αB. For a concentration of up to 10 µM, only a weak 
accumulation of cAMP was detected. This confirms the diastereospecificity of the receptor for both 
signaling pathways.  
 P2Y11 receptors labeled with GFP were used for measurements. In order to verify that the 
GFP tag had no influence on the experimental results, ATP was used on 1321N1 astrocytoma cells 
expressing either the P2Y11-myc/His or the P2Y11-GFP receptor (Figure 26). There were no 
differences in the concentration-dependent elevation of [cAMP]. 
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Figure 25: Levels of cAMP accumulation mediated by the P2Y11-GFP receptor induced by 
different concentrations of 2-propylthio-ATP-αB (A-isomer and B-isomer) and 2-propylthio-
ATP-αB-β,γ-CCl2(B). Data were obtained from 1321N1 astrocytoma cells expressing the P2Y11-GFP 
receptor. The amount of cAMP per mg protein has been determined, as described in methods. 
Numbers of experiments and analyzed cells are given in methods. 
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Figure 26: Levels of P2Y11-myc/His or P2Y11-GFP receptor-mediated cAMP accumulation 
induced by different concentrations of ATP. Data were obtained from 1321N1 astrocytoma cells. 
The amount of cAMP per mg protein has been determined, as described in methods. Numbers of 
experiments and analyzed cells are given in methods. 
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3.3 Potency of 5-OMe-substituted derivatives of UDP on 1321N1 astrocytoma 
cells expressing the human P2Y2, P2Y4, and P2Y6 receptors 
 
3.3.1 Investigation of nucleotide potencies at the human P2Y6 receptor 
expressed in 1321N1 astrocytoma cells 
 
 1321N1 astrocytoma cells were used for the expression of the human P2Y6 receptor. A series 
of novel 5-OMe-substiuted derivatives of UDP was investigated for nucleotide potency at this receptor 
using single-cell Ca2+ measurements (Figure 27). In addition to the OMe-substitution at position 5 of 
the uracil ring, two of the novel nucleotide compounds included a BH3-group at the α-phosphate 
substituting a non-bridging oxygen (5-OMe-UDP-αB and (5-OMe-U)-P3αB-(5-OMe-U). This 
substitution results in the introduction of a new chiral center at the α-phosphate. The Rp configuration 
was assigned to the A-isomers and the Sp configuration to the B-isomers, as described in Ginsburg-
Shmuel et al., 2012. The resulting isomers were investigated separately.  
 
 
nucleotide  substitutions 
5-OMe-UDP  X = O  n = 1 R = OMe 
5-OMe-UDP-αB (A/B)  X = BH3  n = 1 R = OMe 
(5-OMe-U)-P3αB-(5-OMe-U) (A/B)  X = BH3 Y = O   
(5-OMe-U)-P3βB-(5-OMe-U)  X = O Y = BH3   
(5-OMe-U)-P3-(5-OMe-U)  X = O Y = O   
 
Figure 27: Structure of 5-OMe-substituted nucleotide and di-nucleotide derivates of UDP used 
for the investigation of potency and selectivity at the P2Y6 receptor (modified from Ginsburg-
Shmuel et al., 2012). 
 
All nucleotide analogs displayed the ability to activate the P2Y6 receptor. There is a striking 
preference for the A-isomer of 5-OMe-UDP-αB over the B-isomer (Figure 28A). The EC50 value of the 
A-isomer was determined to be 0.008 +/- 0.003 µM, while for the B-isomer it was 4.9 +/- 0.62 µM 
(Table 6). The potency of the A-isomer therefore was more than 600-times higher. A plateau of the 
concentration-response curve of the A-isomer was reached at a nucleotide concentration of 0.1 µM. 
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For the B-isomer, no intracellular Ca2+ response was detected for concentrations below 3 µM, while 
the plateau was reached at 10 µM. 
A similar but less pronounced selectivity of the P2Y6 receptor for the A-isomer was found for 
the di-nucleotide (5-OMe-U)-P3αB-(5-OMe-U) (Figure 28B). The EC50 value for the A-isomer was 
0.14 +/- 0.01 and 2.0 +/- 0.45 µM for the B-isomer. Thus, the A-isomer was about 14-fold more potent 
than the B-isomer. The Ca2+ response amplitudes induced by 0.1 to 10 µM of the B-isomer were 
significantly lower (P < 0.01) than the respective responses to the A-isomer.  
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Figure 28: Concentration-response curves for the rise of [Ca2+]i induced by 5-OMe-substituted 
analogs of UDP in 1321N1 astrocytoma cells expressing the human P2Y6 receptor.  
Responses were induced by A: 5-OMe-UDP-αB (A/B), B: (5-OMe-U)-P3αB-(5-OMe-U) (A/B),  
C: (5-OMe-U)-P3βB-(5-OMe-U), and (5-OMe-U)-P3-(5-OMe-U), D: 5-OMe-UDP, and UDP. Blue 
diamond symbols in D indicate a potential second increase of the Ca2+ response for concentrations of 
5-OMe-UDP higher than 10 µM. The cells were pre-incubated with 2 µM Fura-2 AM for 30 min and the 
change in fluorescence (Δ F340 nm / F380 nm) was detected, as described in methods. Numbers of 
experiments and analyzed cells are given in methods. ** / * = significant differences (P < 0.01; 
P < 0.05, respectively) of Ca2+ response amplitudes to the respective concentrations of nucleotides. 
# = significant differences (P < 0.05) between Ca2+ response amplitudes to 3 µM 5-OMe-UDP-αB(B) 
and 1 µM and 10 µM of 5-OMe-UDP-αB(A). 
 
 The di-nucleotide derivative (5-OMe-U)-P3βB-(5-OMe-U) carries a borano-substitution at the 
middle phosphate, which does not introduce a chiral center at this position. The EC50 value of this 
analog was at 0.2 +/- 0.04 µM (Figure 28C). For (5-OMe-U)-P3-(5-OMe-U), which lacks a borano-
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substitution, a clear plateau for the rise of [Ca2+]i could not be reached for nucleotide concentrations 
up to 100 µM. Therefore, the EC50 value can be estimated to be > 10 µM. A nucleotide concentration 
of 1 µM (5-OMe-U)-P3-(5-OMe-U) yielded a significantly lower (P < 0.01) Ca2+ response amplitude 
than (5-OMe-U)-P3βB-(5-OMe-U). 
 The direct comparison of the potencies of 5-OMe-UDP and the physiological standard agonist 
UDP (Figure 28D) revealed a slightly lower EC50 value for the 5-OMe-substituted nucleotide 
(EC50 = 0.09 +/- 0.02 µM and 0.23 +/- 0.009 µM, respectively). Therefore, 5-OMe-UDP was about 
2.6-fold more potent than UDP. A significantly higher Ca2+ response for 5-OMe-UDP was detected at a 
nucleotide concentration of 0.1 µM (P < 0.01) and 0.2 µM (P < 0.05).  
Figure 28D shows that the plateau of the Ca2+ response can be reached with a concentration 
of 5-OMe-UDP of around 1 µM. However, for 10 µM and 100 µM of 5-OMe-UDP (blue symbols in 
Figure 28D), the amplitude of the intracellular Ca2+ response seems to be further increased. The 
amplitudes for these concentrations of 5-OMe-UDP were in the range of the maximal amplitudes 
observed for the parent compound UDP, but they indicate a possible second increase of the 
intracellular Ca2+ response at the P2Y6 receptor. As the nature of this remains unknown, the EC50 
value of 5-OMe-UDP was deduced from the first phase of the Ca2+ response (from 0.001 µM to 10 µM 
5-OMe-UDP). 
 The rank order of potencies for the tested novel uridine nucleotides was found to be: 
5-OMe-UDP-αB(A) >> 5-OMe-UDP > (5-OMe-U)-P3αB-(5-OMe-U)(A) > (5-OMe-U)-P3βB-(5-OMe-U) = 
UDP > (5-OMe-U)-P3αB-(5-OMe-U)(B) > 5-OMe-UDP-αB(B) > (5-OMe-U)-P3-(5-OMe-U). The most 
potent nucleotide, 5-OMe-UDP-αB(A), was about 29-times more potent than UDP.
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Table 6: Potencies (EC50 values in µM) of UDP and novel 5-OMe-substituted derivatives of UDP 
at the human P2Y6 receptor expressed in 1321N1 astrocytoma cells. Data were derived from 
concentration-response curves given in Figure 28. 
 
Nucleotide  
Intracellular Ca2+ response 
EC50 (µM) +/- SEM 
 5-OMe-UDP-αB (A-isomer, Rp)  0.008 +/- 0.003 (Fig. 28A) 
5-OMe-UDP-αB (B-isomer, Sp)  4.9 +/- 0.62 (Fig. 28A) 
(5-OMe-U)-P3αB-(5-OMe-U) (A-isomer, Rp)  0.14 +/- 0.01 (Fig. 28B) 
(5-OMe-U)-P3αB-(5-OMe-U) (B-isomer, Sp)  2.0 +/- 0.45 (Fig. 28B) 
(5-OMe-U)-P3βB-(5-OMe-U)  0.2 +/- 0.04 (Fig. 28C) 
(5-OMe-U)-P3-(5-OMe-U)  > 10 (Fig. 28C) 
5-OMe-UDP  0.09 +/- 0.02 (Fig. 28D) 
UDP  0.23 +/- 0.009 (Fig. 28D) 
 
 
Major conclusion 
 
Rp-5-OMe-UDP-αB is the most potent P2Y6 receptor agonist known to date. 
 
3.3.2 Investigation of nucleotide specificity for the P2Y6 over the P2Y2 and P2Y4 
receptors expressed in 1321N1 astrocytoma cells 
 
Besides the human P2Y6 receptor, the P2Y2 and P2Y4 receptors can be activated by uridine-
nucleotides. To prove that the Ca2+ responses observed in the concentration-response-experiments in 
Figure 28 indeed were caused by the activation of the P2Y6 receptor, 10 µM of the insurmountable 
P2Y6 receptor antagonist MRS2578 have been added to the 1321N1 astrocytoma cells expressing the 
P2Y6 receptor (Figure 29A). The antagonist was added to the cells 30 min prior to the Ca2+ 
measurements and was co-applied with 10 µM of 5-OMe-UDP-αB(A). MRS2578 was able to 
significantly reduce the intracellular Ca2+ response to the 5-OMe-UDP-αB(A) by circa 78% (P < 0.01).  
Figure 29B shows representative traces of intracellular Ca2+ responses elicited by 10 µM 
5-OMe-UDP-αB(A) without or with the addition of 10 µM of MRS2578. These results demonstrate that 
the observed intracellular Ca2+ responses are indeed mediated by the P2Y6 receptor expressed in the 
1321N1 astrocytoma cells. 
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Figure 29: Nucleotide-induced rise of [Ca2+]i in 1321N1 astrocytoma cells expressing the human 
P2Y6 receptor testing 5-OMe-UDP-αB(A) and the P2Y6 receptor antagonist MRS2578. 
A: Amplitudes of the Ca2+ response after treatment with 10 µM 5-OMe-UDP-αB (A-isomer) compared 
with the respective response amplitude after pre-incubation with the P2Y6 receptor specific antagonist 
MRS2578. B: Representative traces of single-cell Ca2+ measurements with 10 µM 5-OMe-UDP-αB 
(A-isomer) without or with the addition of 10 µM of the P2Y1 receptor antagonist MRS2578. Graphs 
represent mean values from 3 to 5 cells from one experiment. Arrow heads mark the respective start 
of the 1 min applications of Rp-5-OMe-UDP-αB without or with MRS2578. Cells were pre-incubated 
with 2 µM Fura-2/AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, 
as described in methods. ** = Statistically significant (P < 0.01) decrease of [Ca2+]i induced by the 
nucleotide agonist after co-treatment with MRS2578 compared to treatment with nucleotide agonist 
alone. 
 
Although the P2Y2 and P2Y4 receptors prefer uridine-triphosphates over uridine-diphosphates, 
the novel UDP derivates were tested on 1321N1 astrocytoma cells expressing the P2Y2 and P2Y4 
receptors as well as on wildtype cells (Figure 30). In cells expressing the P2Y2 receptor, the 
physiological agonist UTP evoked a strong intracellular Ca2+ response (Figure 30A). However, none of 
the novel 5-OMe-substituted derivatives of UPD caused a substantial response at a nucleotide 
concentration of 100 µM (50 µM in the case of 5-OMe-UDP). In cells expressing the P2Y4 receptor, 
UTP treatment yielded strong Ca2+ responses (Figure 30B). Responses to all novel nucleotide 
derivatives were significantly lower (P < 0.01). Only 5-OMe-UDP at concentrations of 10 µM and 
50 µM caused a notable response. In 1321N1 astrocytoma wildtype cells, all the tested nucleotides 
were inactive (Figure 30C). 
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Figure 30: Amplitudes of the rise of [Ca2+]i in 1321N1 astrocytoma cells induced by novel 
5-OMe-substituted analogs of UDP. Responses were induced in cells expressing the human  
A: P2Y2 receptor, B: P2Y4 receptor, or in C: 1321N1 astrocytoma wildtype cells using UTP, UDP, 
5-OMe-UDP-αB (A-isomer and B-isomer), (5-OMe-U)-P3αB-(5-OMe-U) (A-isomer and B-isomer), 
(5-OMe-U)-P3βB-(5-OMe-U), (5-OMe-U)-P3-(5-OMe-U), or 5-OMe-UDP. The cells were pre-incubated 
with 2 µM Fura-2 AM for 30 min and the change in fluorescence (Δ F340 nm / F380 nm) was detected, 
as described in methods. Numbers of experiments and analyzed cells are given in methods.  
** = significant difference (P < 0.01) of Ca2+ response amplitudes between UTP and the tested 
nucleotide derivatives. 
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4. Discussion 
4.1 Characterization of the Alanine-(87)-Threonine mutation of the human P2Y11 
receptor  
 
 The investigation of naturally occurring genetic polymorphisms leads to new insights about the 
functional roles of mutated amino acids in receptor activity. The identification and careful analysis of 
resulting aberrant receptor functions can answer the question of how specific receptor mutations affect 
cellular processes, and how that may contribute to the development of disorders. A SNP of the human 
P2Y11 receptor, which causes a switch from the non-polar amino acid alanine to the polar threonine at 
position 87 (A87T), was statistically connected to an increased risk for AMI and elevated levels of C-
reactive protein (Amisten et al., 2007). In our work, the first pharmacological and functional 
characterization of the P2Y11A87T receptor was undertaken. For this, the receptor was expressed in 
the human HEK293 and 1321N1 astrocytoma cell lines. A comparative overview of nucleotide-induced 
cellular responses mediated by the non-mutated and the mutated P2Y11 receptors is given in Table 7 
and Table 8 for 1321N1 astrocytoma cells and HEK293 cells, respectively. 
The A87T mutation of the P2Y11 receptor impairs Ca2+ signaling, but this impairment is found 
only in cells co-expressing the P2Y1 receptor. 
In 1321N1 astrocytoma cells, the P2Y11 receptor-specific agonist BzATP induced identical 
intracellular Ca2+ responses irrespective of whether the wildtype P2Y11 receptor or the mutated 
P2Y11A87T receptor was expressed (Figure 4A). 1321N1 astrocytoma cells provide a P2Y receptor-
null background (Figure 8B). Thus, isolated responses of the P2Y receptors expressed in these cells 
are detected. In line with the finding of Ecke et al. (2008), BzATP was a potent agonist at the wildtype 
P2Y11 receptor expressed in HEK293 cells (Figure 4B). Importantly, the Ca2+ response to BzATP of 
HEK293 cells was completely absent when the mutant P2Y11A87T receptor was expressed (Figure 
4B). In these HEK293 cells, endogenous P2Y1 receptors are present. This was verified here by 
evoking a Ca2+ response using the P2Y1 receptor-specific agonist 2-MeS-ADP (Figure 8A). Also, the 
ATP-induced response was inhibited by the P2Y1 receptor-specific antagonist MRS2179 (Figure 8A), a 
2’-deoxy-adenosine derivative featuring phosphate groups at the 3’ and the 5’ position and an 
N6-methyl substituent at the nucleobase. Based on multiple lines of evidence using GST-pulldown, 
FRET, immunocytochemistry, and siRNA experiments, as well as pharmacological analysis, the work 
by Ecke et al., (2008) verified that the P2Y11 receptor and the P2Y1 receptor form hetero-oligomers 
with a unique functionality. This can be seen either in HEK293 cells or in 1321N1 astrocytoma cells, 
which express both receptors. This receptor interaction is very likely to take place as well between the 
P2Y11A87T and P2Y1 receptors in HEK293 cells. In line with this notion, we found the complete loss of 
the BzATP-induced Ca2+ response in P2Y11A87T receptor-expressing HEK293 cells, but not in 
1321N1 astrocytoma cells, which do not allow the formation of the receptor oligomers. It is thus 
important to note that the A87T mutation per se is not sufficient to alter the P2Y11 receptor 
functionality. 
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 At the P2Y11 and P2Y11A87T receptors expressed in 1321N1 astrocytoma cells, 2-MeS-ADP is 
only a weak agonist (Figure 5A). In HEK293 cells expressing the P2Y11A87T receptor, the potency of 
this agonist is significantly lower than it is in cells expressing the wildtype P2Y11 receptor (Figure 5B). 
Interestingly, the expression of the non-mutated P2Y11 wildtype receptor already leads to a decrease 
of the 2-MeS-ADP potency when compared with HEK293 wildtype cells. This very likely reflects the 
fact that in HEK293 wildtype cells, the response to 2-MeS-ADP is solely carried by the endogenous 
P2Y1 receptor. In the P2Y11 receptor-expressing HEK293 cells, a response of the functionally distinct 
P2Y1/P2Y11 hetero-oligomer is observed. The additional reduction of potency of 2-MeS-ADP in 
HEK293 cells expressing the P2Y11A87T receptor indicates that the A87T mutation has indeed a 
detrimental effect on the P2Y1/P2Y11 oligomer signaling function. 
 This latter notion is further solidified by the comparative analysis of ATP potencies in 1321N1 
astrocytoma cells and HEK293 cells. There was, again, no difference in nucleotide potency between 
either 1321N1 astrocytoma cells expressing the P2Y11 receptor or cells expressing the P2Y11A87T 
receptor (Figure 6A). Using HEK293 cells, a small but significant reduction of the EC50 value of ATP at 
the P2Y11A87T receptor was found when compared with the P2Y11 receptor (Figure 6B). It is important 
to consider that, in contrast to the synthetic nucleotides BzATP and 2-MeS-ADP, ATP is a 
physiological agonist for both the P2Y1 and P2Y11 receptors with important functions throughout the 
human organism. Although the reduction of ATP potency at P2Y11A87T receptor-expressing HEK293 
cells was only 1.6-fold (Table 2), the severity of the pathological consequences of the receptor 
mutation might be due to the long-term build-up of small cellular aberrations. 
 
Table 7: Nucleotide-induced cellular responses mediated by the P2Y11A87T, wildtype P2Y11, 
and P2Y1 receptor in 1321N1 astrocytoma cells in absence of endogenous P2Y receptor 
expression. ([1] = Major et al., 2004b; [2] = Abbracchio et al., 2006; [3] = Ecke et al., 2008) 
 
 
1321N1 astrocytoma cells  
P2Y receptor expression (transfection) 
Response P2Y11 P2Y11A87T P2Y1 
Intracellular Ca2+ 
signaling 
 
Strong response to 
ATP  
 
Strong response to 
ATP 
 
Strong response to 
ATP[1]  
 
Strong response to 
BzATP 
 
Strong response to 
BzATP 
 
No response to 
BzATP 
 
Weak response to  
2-MeS-ADP 
 
Weak response to  
2-MeS-ADP  
 
Strong response to  
2-MeS-ADP 
 
 
> Identical to the 
wildtype P2Y11 
receptor 
 
Intracellular 
cAMP signaling 
 
Strong response to 
ATP 
 
Strong response to 
ATP  
 
(No coupling to Gs 
or Gi signaling[2]) 
 
 
> Identical to the 
wildtype P2Y11 
receptor 
 
Nucleotide-
induced receptor 
internalization 
No effect [3] Not determined Strong effect [3] 
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Table 8: Nucleotide-induced cellular responses mediated by the P2Y11A87T, P2Y11A87S, 
P2Y11A87Y, and wildtype P2Y11 receptor in HEK293 cells in presence of endogenous P2Y1 
receptors.  
 
 
HEK293 cells 
 P2Y receptor expression (transfection) 
Response P2Y11 P2Y11A87T P2Y11A87S P2Y11A87Y 
Intracellular Ca2+ 
signaling 
 in comparison with the wildtype P2Y11 receptor 
 
Strong response to 
ATP 
 
Reduced response to 
ATP  
 
Reduced response to ATP 
 
Strong response to 
BzATP 
 
No response to 
 BzATP 
 
Similar response to BzATP 
 
Strong response to  
2-MeS-ADP 
 
 
Reduced response to 
2-MeS-ADP 
  
Similar response to 2-MeS-ADP  
Intracellular cAMP 
signaling 
 
Strong response to 
ATP 
 
 
Reduced response to 
ATP 
 
Not determined Not determined 
Nucleotide-
induced receptor 
internalization 
 
Strong ATP-induced 
receptor 
internalization 
 
No effect 
 
Weak ATP-induced 
receptor 
internalization 
 
No effect 
 
Strong BzATP-
induced receptor 
internalization 
 
 
Strong BzATP-
induced receptor 
internalization 
 
Long-term 
intracellular Ca2+ 
signaling 
 
Strong 
desensitization after 
60 min challenge 
with ATP 
 
 
Stronger 
 desensitization after  
60 min challenge with  
ATP  
 
Not determined  
Weak recovery of the 
response after a 
following 90 min 
incubation in the 
absence of ATP 
 
 
Strong recovery of the  
response after a 
following 90 min  
incubation in the  
absence of ATP 
 
 
Due to the change from a non-polar alanine to a polar threonine residue at position 87 of the 
P2Y11 receptor, amino acid polarity was suggested by Amisten and coworkers in 2007 to be the cause 
for altered receptor function. To test this hypothesis, additional P2Y11 receptor mutants were 
generated by us using site-directed mutagenesis. In the case of the P2Y11A87S receptor, the alanine-
87 was replaced with a small polar serine residue. The P2Y11A87Y receptor featured a bulky polar 
threonine residue at the respective position within the protein. It was found that the A87S and A87Y 
mutations of the P2Y11 receptor rescue the potency of BzATP and 2-MeS-ADP in HEK293 cells (Table 
2). Since the P2Y11A87S and P2Y11A87Y receptors show restored nucleotide-induced Ca2+ 
responses, amino acid polarity can be ruled out to be the reason for the observed alterations of 
P2Y11A87T receptor functionality. It is noteworthy that the maximal Ca2+ amplitudes to BzATP and 
2-MeS-ADP of the P2Y11A87S receptor were higher than those of the other P2Y11 mutant receptors 
and the wildtype P2Y11 receptor (Figure 4C and Figure 5C). Analyzing the fluorescence intensities of 
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the C-terminal GFP tags of the P2Y11 receptors used in this study, the expression level of the 
P2Y11A87S receptor in HEK293 cells was found to be comparable to that of the other receptors 
(Figure 9). Only for the P2Y11A87Y receptor, the expression level was slightly reduced, but Ca2+ 
responses mediated by this receptor were comparable to those of P2Y11 receptor-expressing cells. 
Thus, different expression levels cannot be the cause of the differences in potencies or maximal 
response amplitudes observed for the different nucleotides. Also, there were no significant differences 
of maximal Ca2+ responses to ATP induced by any of the P2Y11 receptors (Figure 6). Therefore, the 
relatively higher maximal responses to BzATP and 2-MeS-ADP of the P2Y11A87S receptor have little 
physiological relevance. 
Other endogenous Gq-coupled P2Y receptors with preference for uridine and/or adenine 
nucleotides could contribute to the nucleotide-induced intracellular Ca2+ responses described above. 
We found that besides the P2Y1 receptor, the P2Y4 receptor is likely to be the only other Gq-coupled 
P2Y receptor that is functionally expressed in the HEK293 cells. The cells show a rise of [Ca2+]i after 
treatment with ATP and UTP (Figure 8). Both nucleotides can activate the P2Y2 receptor and UTP is 
the physiological standard agonist for the P2Y4 receptor. However, the response to ATP was 
completely inhibited by the P2Y1 receptor-specific antagonist MRS2179. Therefore, we conclude that 
there was no ATP-induced P2Y2 receptor activation and the P2Y2 receptor can thus also be ruled out 
to be the source for the UTP-induced Ca2+ response.  
 Our data show that the expression of the P2Y11A87T receptor in HEK293 cells can lead to 
reduced nucleotide-induced intracellular Ca2+ responses when compared with cells expressing the 
P2Y11 receptor or wildtype cells. However, those comparisons are based on separate experiments 
using cells from different cultures (Table 2). In order to verify our findings under identical experimental 
conditions, we investigated transfected (GFP-positive) and non-transfected (GFP-negative) cells of the 
same cell culture simultaneously (Figure 11). Responses of GFP-positive cells expressing the 
P2Y11A87T receptor under all conditions were always equal to or lower than the responses of the 
respective GFP-negative cells, as can easily be deduced from the F-values shown in Table 3. This is 
in line with the hypothesis that the A87T mutation is detrimental for the P2Y1/P2Y11 receptor oligomer 
function and confirms the data from the concentration-response experiments. Responses of GFP-
negative cells were comparable to those of the wildtype HEK293 cells of a separate control culture, 
thus confirming the wildtype nature of GFP-negative cells.  
In line with the concentration-response data (Figure 4), the P2Y11A87T receptor in GFP-
positive cells showed no response to BzATP, which is similar for the GFP-negative cells (Table 3). On 
the other hand, the P2Y11 receptor in GFP-positive cells mediated a strong response to BzATP.  
Similar to the concentration-response data (Figure 5), GFP-positive cells with P2Y11 or 
P2Y11A87T receptor-expression showed a significantly lower response amplitude induced by 2-
MeS-ADP than GFP-negative cells (Figure 12A). We attribute this to the P2Y1/P2Y11 receptor 
interaction in the GFP-positive cells.  
Treatment of HEK P2Y11 receptor cultures with the physiological standard agonist ATP 
showed a slight but significant increase of the response amplitude in comparison with the GFP-
negative cells (Figure 12B). The same treatment applied to HEK P2Y11A87T receptor cultures gave a 
significantly reduced response amplitude for GFP-positive cells, when compared with GFP-negative 
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cells. A critical experiment was the use of the P2Y1 receptor-specific antagonist MRS2179 (Figure 
12B). The antagonist was able to completely inhibit the response to ATP in GFP-negative cells in all 
cultures including the wildtype HEK293 cells of a separate control culture. This result confirms that 
these ATP-induced intracellular Ca2+ response are based on the P2Y1 receptor activity. Interestingly, 
while GFP-positive cells expressing the P2Y11 receptor were unaffected by the antagonist, the 
response to ATP of P2Y11A87T receptor expressing cells was inhibited by the antagonist. This 
confirms a functional difference of the P2Y11 and P2Y11A87T receptors, when they are expressed in 
HEK293 cells. 
The GFP-tag of the receptors was not the reason for the observed alterations of the Ca2+ 
response amplitudes, since HEK293 cells expressing the PAR2-GFP receptor (a GPCR, which cannot 
be activated by extracellular nucleotides) and GFP-negative cells within the same culture showed 
identical ATP-induced Ca2+ responses (Table 4).  
The deleterious effect of the A87T mutation of the P2Y11 receptor in cells which co-express the 
P2Y1 receptor is confirmed in double-transfected 1321N1 astrocytoma cells. 
The most striking result of the single-cell Ca2+ measurements discussed above was the 
complete absence of BzATP-induced intracellular Ca2+ response of HEK293 cells expressing the 
P2Y11A87T receptor. This observation was not made with 1321N1 astrocytoma cells expressing this 
receptor (Figure 4). As we attribute this substantial reduction of nucleotide potency in HEK293 cells to 
an impaired functionality of the P2Y11A87T receptor interaction with the endogenous P2Y1 receptor, it 
was critical to validate this hypothesis in the P2Y receptor-null background of 1321N1 astrocytoma 
cells. Therefore, the P2Y1 receptor was co-expressed in 1321N1 astrocytoma cells with either the 
wildtype P2Y11 receptor or the mutant P2Y11A87T receptor. The expression of the P2Y11 receptor was 
verified via detection of the GFP fluorescence, and the respective cells were challenged with 1 µM of 
the P2Y11 receptor-specific agonist BzATP (Figure 13). The functional co-expression of the P2Y1 
receptor was verified with 1 µM 2-MeS-ADP given after at least 2 min recovery time following the 
detection of the BzATP-induced response (Figure 14). This concentration of 2-MeS-ADP is high 
enough to yield a strong P2Y1 receptor-mediated Ca2+ response but too low to activate the P2Y11 or 
P2Y11A87T receptors (Figure 5A, D). Accordingly, in control experiments with 1321N1 cells expressing 
only the P2Y11 or the P2Y11A87T receptor there was no response to the 2-MeS-ADP stimulus and a 
strong response to BzATP. In 1321N1 cells solely expressing the P2Y1 receptor, a negligible response 
to BzATP was detected, and a strong response to 2-MeS-ADP could be observed. Importantly, 
1321N1 cells co-expressing the P2Y11A87T receptor and the P2Y1 receptor showed a significantly 
reduced (P < 0.01) Ca2+ response amplitude to BzATP, when compared with cells co-expressing the 
P2Y11 and the P2Y1 receptor.  
Furthermore, the BzATP-induced response amplitude of 1321N1 cells co-expressing the 
P2Y11 and the P2Y1 receptor was identical to the respective response of single-transfected cells 
expressing the P2Y11 or P2Y11A87T receptors without the P2Y1 receptor. Hence, these results are in 
line with our findings derived from HEK293 cells. Therefore, the A87T mutation of the P2Y11 receptor 
has significant consequences for cells co-expressing the P2Y1 receptor. The functional interaction of 
P2Y1 and P2Y11 receptors has been demonstrated by Ecke et al. in 2008 to take place in HEK293 
cells as well as in 1321N1 cells. Therefore, we have good reason to assume that the SNP causing the 
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A87T mutation has a deleterious effect on the function of the receptor oligomer in all human cells co-
expressing the respective receptors. The reduction of the response to BzATP of 1321N1 cells co-
expressing the P2Y1 and P2Y11A87T receptors was not as severe as in HEK293 cells, however. This 
might be due to different cell type-specific characteristics. Along the same line, the response to the 
test concentration of 1 µM of 2-MeS-ADP was identical in all 1321N1 astrocytoma cells with P2Y1 
receptor expression, while in HEK293 cells expressing the P2Y11 receptors a reduced Ca2+ response 
was found. 
The A87T mutation of the P2Y11 receptor is detrimental to cAMP signaling in HEK293 cells. 
 The human P2Y11 receptor is coupled not only to Gq-mediated intracellular Ca2+ signaling, but 
also to Gs-mediated activation of adenylyl cyclase. Since a deleterious effect of the A87T mutation on 
P2Y11 receptor functions might also affect this signaling pathway, the ATP-induced accumulation of 
intracellular cAMP was investigated in 1321N1 astrocytoma cells and HEK293 cells (Figure 10). In 
accordance with the data from the Ca2+ measurements, a significant reduction in intracellular cAMP 
generation could be found only in HEK293 cells expressing the P2Y11A87T receptor, but not in 
1321N1 astrocytoma cells. Thus for Gq and Gs signaling, an altered P2Y11 receptor function was 
detected only in those cells, which co-express the P2Y1 receptor. This further underlines our 
hypothesis that the A87T mutation primarily affects the interaction of the P2Y11 and P2Y1 receptors in 
respective cells. 
Nucleotide-induced receptor internalization is not found in HEK293 cells expressing the 
P2Y11A87T receptor. 
 The formation of P2Y1/P2Y11 receptor-oligomers in HEK293 cells and 1321N1 astrocytoma 
cells has also been demonstrated by Ecke et al. in 2008 in experiments studying the nucleotide-
induced internalization of the P2Y11 receptor. The P2Y11 receptor is unable to undergo internalization, 
when expressed in the P2Y receptor-null background of 1321N1 astrocytoma cells. However, the 
P2Y11 receptor acquires this ability, when the P2Y1 receptor is additionally expressed. This effect was 
found in transfected 1321N1 astrocytoma cells, or in HEK293 cells. Our data from Ca2+ and cAMP 
measurements discussed above support the hypothesis that the A87T mutation of the P2Y11 receptor 
interferes with P2Y1/P2Y11 receptor-oligomer functions. 
Thus, we compared the nucleotide-induced internalization of the wildtype P2Y11 receptor with 
that of the P2Y11 receptor mutants generated by us. The receptors were expressed in HEK293 cells 
and incubated for 60 min with 100 µM of the physiological standard agonist ATP or 100 µM of the 
P2Y11 receptor-specific agonist BzATP (Figure 18). The P2Y11A87T receptor showed no sign of 
internalization under these conditions. The wildtype P2Y11 receptor, on the other hand, was strongly 
internalized as seen by the prominent accumulation of intracellular GFP fluorescence. Similar to the 
P2Y11A87T receptor, the P2Y11A87Y receptor was not internalized. The P2Y11A87S mutant receptor, 
however, showed slight ATP-induced internalization and a strong BzATP-induced internalization.  
The mutant P2Y11 receptors which do not display internalization upon nucleotide treatment are 
functional receptors since they are capable of inducing intracellular Ca2+ or cAMP signaling. It has 
been proposed that the binding of different ligands to GPCRs may evoke physiologically active 
receptor conformations with different signaling specificity (Fergusson et al., 2001; Kenakin et al., 2007; 
Galandrin et al., 2007; Hoffmann et al., 2008a). These ligand-dependent conformations may 
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selectively trigger some downstream signaling pathways of the receptor, while other possible signaling 
pathways remain inactive. Following this concept, agonist-selective signaling of P2Y receptors via G 
proteins or β-arrestins may differentially activate Ca2+ signaling, cAMP signaling, β-arrestin-mediated 
ERK phosphorylation, receptor internalization, or possibly other signaling pathways. This concept was 
confirmed by Hoffmann and coworkers (2008b) who found that the recruitment of either β-arrestin 1 or 
β-arrestin 2 to the P2Y2 receptor depends on the type of nucleotide, which is used for activating the 
receptor. ATP treatment would result in stronger β-arrestin 2 than β-arrestin 1 translocation, while UTP 
induction triggered equal β-arrestin 1 and 2 recruitment. The µ-opioid receptor provides another 
example of agonist-dependent signaling. Morphine is not able to trigger µ-opioid receptor 
phosphorylation and internalization, while etorphine can cause these processes (Zhang et al., 1998). 
Only after a non-physiological over-expression of GRK2, morphine-induced phosphorylation of the 
µ-opioid receptor and subsequent internalization has been detected. 
The results of our study demonstrate that the A87T mutation of the P2Y11 receptor affects G 
protein signaling and receptor internalization alike. The severity of the impairment of the P2Y11 
receptor functions, however, is not equal for all nucleotides and signaling pathways. 
The A87T mutation of the P2Y11 receptor enhances desensitization, but improves 
resensitization of the intracellular Ca2+ response in comparison with the non-mutated P2Y11 
receptor. 
The P2Y11A87T receptor completely lacks nucleotide-induced internalization in HEK293 cells 
over a time-span of 60 min. This indicates that the patho-physiological relevance of the mutation could 
depend more on the alteration of the long-term rather than short-term activity of the receptor. 
Eventually, this could lead to a higher cell responsiveness to prolonged exposures to natural activating 
nucleotides, like ATP.  
Therefore, long-term Ca2+ measurements with HEK293 cells expressing the P2Y11, 
P2Y11A87T, or P2Y11A87S receptors were conducted (Figure 20A). The cells were challenged with a 
sustained 30 min exposure to ATP (100 µM) to allow receptor activation, subsequent response 
desensitization and, if possible, receptor internalization. After a following 60 min recovery period in 
nucleotide-free buffer, the retained cell responsiveness was determined by application of a 1 min 
pulse of ATP (100 µM; Figure 19). After the 30 min-treatment with ATP, cells expressing the P2Y11 
receptor showed a Ca2+ response level of 25% of the response at the start of the measurement 
(t = 0 min; Figure 20A). The cells expressing the P2Y11A87T or P2Y11A87S receptor showed a 
significantly lower Ca2+ response level of 15% and 12% of the response at 0 min, respectively. At first 
glance, one would expect the opposite result, as 30 min of nucleotide treatment triggers the 
internalization of the wildtype P2Y11 receptor, while the P2Y11A87T receptor would remain at the 
plasma membrane and the P2Y11A87S receptor shows light internalization only (Figure 18). Therefore, 
the entirety of the P2Y11A87T receptors and the majority of the P2Y11A87S receptors would still be 
accessible to extracellular nucleotides and a higher resulting Ca2+ level was to be expected. However, 
it is known that GPCR desensitization due to phosphorylation via GRKs or second messenger kinases 
precedes receptor internalization (Ferguson et al., 2001). Therefore, it is possible that P2Y11A87T and 
P2Y11A87S receptor desensitization via phosphorylation takes place despite the lack of receptor 
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internalization. The latter could be a consequence of a dysfunctional β-arrestin recruitment or binding 
and would not affect desensitizing receptor kinase activity. 
After the final ATP-treatment at 90 min, hence at the end of the 60 min recovery period 
following the 30 min desensitization phase, the cells expressing the P2Y11 receptor showed a poorly 
improved Ca2+ response (34% of the response at 0 min; Figure 20A). The cells expressing the 
mutated receptors showed a Ca2+ response of 51% (P2Y11A87T receptor) and 57% (P2Y11A87S 
receptor) of the respective responses at 0 min. This means that the HEK293 cells expressing mutated 
P2Y11 receptors showed a much greater Ca2+ response recovery than cell expressing the non-mutated 
receptor (Figure 20A). This could be a consequence of the malfunctioning receptor internalization, as 
the receptors are still in place at the plasma membrane. On the other hand, dephosphorylation and 
resensitization of GPCRs were reported to depend on the internalization into endosomes and 
subsequent recycling to the plasma membrane (Ferguson et al., 2001). Therefore, the mechanistic 
details of the desensitization process of the P2Y11A87T and P2Y11A87S receptor-induced responses 
remain to be elucidated. It is possible that the observed desensitization of the intracellular Ca2+ 
responses is not caused at the receptor level, but it could take place at some other point of the 
downstream signaling pathway. This possibility has to be considered, since Ecke et al. (2008) found 
that the P2Y11 receptor is not capable of nucleotide-induced internalization in 1321N1 astrocytoma 
cells. Thus, P2Y11 receptor desensitization in a physiological context without P2Y1 receptor co-
expression would have to rely on a mechanism, which does not involve P2Y11 receptor internalization 
into endosomes. 
General conclusions: Genetic polymorphisms of the P2Y11 receptor might contribute to 
neurodegenerative diseases and immune disorders via altered long-term cell activity. 
Our experimental data show that the effect of the A87T mutation on downstream signaling 
depends on the co-expression of the P2Y1 receptor and, most likely, the formation of the P2Y1/P2Y11 
receptor hetero-oligomers. Thus, future investigations of the A87T polymorphism of the human P2Y11 
receptor should consider possible P2Y1 receptor interactions. 
The P2Y11A87T receptor can activate ATP-induced Ca2+ and cAMP signaling in HEK293 cells, 
but a significant reduction of the potency of ATP was found. This possibly impairs long-term cellular 
functions. The mutated receptor fails to internalize in consequence of the ATP stimulus in P2Y1 
receptor-expressing HEK293 cells. This is expected to have a major impact on the regulation of P2Y11 
receptor-induced intracellular responses.  
We found an apparently faster resensitization of the Ca2+ response in cells expressing the 
P2Y1 plus the P2Y11A87T receptor in long-term experiments, which could be due to the lack of 
receptor internalization. We suggest that this might ultimately result in increased patho-physiological 
cell activity over an extended period of time. As the SNP leading to the A87T mutation has been linked 
to an increased risk for AMI (Amisten et al., 2008), the SNP possibly contributes to the patho-
physiological activity of immune cells in atherosclerosis, which is the main cause for AMI. Several 
immune cells known for their role in atherosclerosis, such as dendritic cells, macrophages, and mast 
cells co-express the P2Y1 and P2Y11 receptors. Near the necrotic cores of atherosclerotic sites, these 
cells are exposed to high concentrations of extracellular nucleotides, including ATP, due to a long-
lasting chronic inflammation (Tabas, 2010).  
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Another SNP in the 3’ UTR of the P2RY11 gene was connected to narcolepsy with cataplexy, 
an auto-immune disease resulting in the loss of hypocretin-producing neurons (Kornum et al., 2011). 
This SNP was reported result in impaired P2Y11 receptor-mediated protection against ATP-induced 
cell death. Furthermore, reduced expression levels of the P2Y11 receptor in CD8+ T-lymphocytes and 
natural killer cells were found, which could have a long-term effect on the nucleotide-induced activity 
of these cells. 
Therefore, genetic polymorphisms of the P2Y11 receptor might primarily affect long-term cell 
activity and could by this way contribute to the pathogenesis of neurodegenerative diseases and 
immune disorders in general. Thus, the modulation of the P2Y11 receptor activity is a promising goal 
for future therapeutic approaches.  
 
4.2 Novel nucleotide derivatives as agonists for the human P2Y11 receptor or 
the P2Y6 receptor 
 
4.2.1 Evaluation of 2-propylthio-substituted derivatives of ATP as P2Y11 
receptor agonists 
 
The nucleotide analog AR-C67085 (2-propylthio-ATP-β,γ-CCl2) has been found to be one of 
the most potent agonists at the human P2Y11 receptor (Communi et al., 1999). In this study by 
Communi and coworkers, the potency for the P2Y11 receptor-mediated elevation of IP3 in 1321N1 
astrocytoma cells has been reported to be 7-fold higher than that of the physiological standard agonist 
ATP, 1.2-fold higher than that of the P2Y11 receptor-specific BzATP, and 1.5-fold higher than that of 
ATP-γS. In our study, we aimed to develop a P2Y11 receptor agonist with increased potency and 
enhanced selectivity. Therefore we used analogs based on the structure of AR-C67085. 2-propylthio 
and β,γ-dichloromethylene substituents, which both can be found in AR-C67085, were introduced into 
ATP in different combinations with Pα-borano or Pα-thio substitutions (Figure 21). With the Pα 
substitutions, we specifically aimed to increase agonist selectivity for the P2Y11 receptor over its 
closest homolog, the P2Y1 receptor. These receptors display opposite diastereoselectivity for Pα-
substituted nucleotides as has been described before in our laboratory (Major et al., 2004b; Ecke et 
al., 2006). It has been suggested by Major et al. (2004b) that the isomeric preference of the P2Y1 
receptor for certain isomers of Pα-substituted nucleotides has its origin in the lost interaction between 
a Pα-oxygen and a Mg2+ ion, which is coordinated within the binding pocket of the receptor. We 
assume a similar mechanistic reason for the diastereoselectivity of the P2Y11 receptor. Ecke et al. 
(2006) reported that the preferred isomers of Pα-substituted nucleotides show improved potencies at 
the P2Y1 and P2Y11 receptors. We therefore expected increased agonist potency by using Pα-
substituted derivatives of AR-C67085. 
Here, we analyzed the nucleotide-induced intracellular Ca2+ responses in 1321N1 astrocytoma 
cells mediated by the adenine nucleotide-accepting P2Y1, P2Y2, and P2Y11 receptors. We also studied 
cAMP responses induced by the P2Y11 receptor. This lead to important conclusions regarding 
structure-activity relationships of the novel nucleotides.  
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The P2Y11 receptor prefers Sp(B)-isomers of the Pα-borano substituted analogs over the 
respective Rp(A)-isomers. 
The Sp(B)-isomers of 2-propylthio-ATP-αB and 2-propylthio-ATP-αB-β,γ-CCl2 show higher 
potency at the P2Y11 receptor than the respective Rp(A)-isomers (Table 5). The B-isomer of the 
former was about 13-fold more potent than its A-isomer, while the B-isomer of the latter was about 
3-fold more potent. This is in accordance with the previous results of Ecke et al. (2006). There, the 
Sp-isomer of ATP-αB was about 7-fold more potent at the P2Y11 receptor than the respective 
Rp-isomer, which was equipotent to ATP. The preferred isomer of the Pα-thio substituted derivative, 
Rp-ATP-αS, was found in this study to be about 6-fold more potent than the respective Sp-isomer. 
Interestingly, in our study the P2Y11 receptor showed no significant preference for either isomer of 
2-propylthio-ATP-αS and 2-propylthio-ATP-αS-β,γ-CCl2 (Figure 22A/C). Thus, only the addition of a 
Pα-borano group lead to diastereoselectivity at the P2Y11 receptor and also yielded the most potent 
analogs. Nevertheless, all Pα-modifications lead to a substantial increase of potency compared with 
ATP.  
 
A 
 
B 
 
2-propylthio-ATP-αB 
EC50 (P2Y11 receptor) = 0.03 µM (B-isomer) 
2-propylthio-ATP-αB-β,γ-CCl2  
EC50 (P2Y11 receptor) = 0.03 µM (B-isomer) 
 
Figure 31: Structure of the most potent of the 2-proplythio-substituted derivatives of ATP 
tested at the human P2Y11 receptor expressed in 1321N1 astrocytoma cells.  
A: 2-propylthio-ATP-αB, B: 2-propylthio-ATP-αB-β,γ-CCl2. 
 
Combined modifications at the C2 position and at the α-phosphate of ATP can result in 
strongly enhanced agonist activity at the P2Y11 receptor. 
 Computational modeling of the P2Y11 receptor by Zylberg et al. (2007) revealed the existence 
of a confined hydrophobic pocket near the C2 position of an ATP molecule coordinated inside the 
receptor binding pocket. This has prompted the hypothesis that modifications at the C2 position of 
ATP might enhance nucleotide potency at the P2Y11 receptor due to improved nucleotide binding. 
However, nucleotides with C2 substitutions like 2-MeS-ATP and 2-Cl-ATP have been found by Ecke et 
al. in 2006 to be only weak agonists of the P2Y11 receptor. Importantly, the addition of Pα-borano or 
Pα-thio groups to these analogs significantly increased the nucleotide potency. The combination of C2 
and Pα substitutions in 2-MeS-ATP-αB lead to one of the most potent P2Y11 receptor agonist in the 
study of Ecke and coworkers (EC50 value for the B-isomer = 0.26 µM; EC50 value for ATP = 2.83 µM).  
Similar to the C2-substituted ATP derivatives in these earlier studies, 2-propylthio-ATP 
showed no enhanced potency in the present study, when compared with ATP (EC50 = 2.5 µM and 2.6 
µM, respectively; Table 5). However, the combination of the Pα-borano substitution with the 
2-propylthio group remarkably reduced the EC50 value. 2-propylthio-ATP-αB (Figure 31) turned out to 
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be one of the most potent P2Y11 receptor agonist in the present study with an EC50 value for the B-
isomer of 0.03 µM. This novel P2Y11 receptor agonist was 87-times more potent than the physiological 
standard agonist ATP. As the B-isomers of neither ATP-αB (EC50 = 0.34 µM; Ecke et al., 2006) nor 
2-propylthio-ATP (EC50 = 2.5 µM) are as potent as the B-isomer of 2-propylthio-ATP-αB, the 
combination of the C2 and the Pα modifications in the latter nucleotide are the reason for substantial 
increase of potency.  
The dichloromethylene modification between β- and γ-phosphates does not affect nucleotide 
potency of ATP derivatives at the P2Y11 receptor. 
 The introduction of a β,γ-dichloromethylene group to 2-propylthio-ATP-αB has lead only to a 
minor enhancement of potency of the A-isomer of 2-propylthio-ATP-αB-β,γ-CCl2 (Figure 31), in 
comparison to the A-isomer of 2-propylthio-ATP-αB (Table 5). The potency of the B-isomer was 
actually identical, with an EC50 value of 0.03 µM. Thus, the addition of the β,γ-CCl2 group was not 
beneficial regarding nucleotide potency. Moreover, in 2-propylthio-ATP-αS-β,γ-CCl2 the β,γ-CCl2 
group was detrimental to the potency of both isomers when compared with 2-propylthio-ATP-αS. 
Substitutions of the bridging oxygen in the phosphate chain can be used to increase 
resistance against cleavage by e-NTPDases (Eliahu et al., 2010). Nevertheless, AR-C67085, which 
carries a CCl2 substituent between the β- and γ-phosphates, was reported to have a short half-life in 
human of about 2 min (Humphries et al., 1995). This, however, was likely due to cleavage between 
the α- and β-phosphates, as the diphosphate nucleotide metabolite of AR-C67085 has not been 
detected. Pα-borano substitutions have been reported to increase nucleotide stability against 
hydrolysis by NPP1 and NPP3 before (Nahum et al., 2006; Ginsburg et al., 2012). Hence, the 
combined modifications in 2-propylthio-ATP-αB-β,γ-CCl2 are expected to provide enhanced resistance 
against hydrolysis compared to 2-propylthio-ATP-αB. Thus, despite the fact that the B-isomers of both 
analogs showed identical EC50 values, 2-propylthio-ATP-αB-β,γ-CCl2 is possibly the more promising 
nucleotide scaffold for future drug development.  
The dichloromethylene modification between β- and γ-phosphates improves P2Y11 receptor 
specificity. 
 It is an important criterion for drug candidates to specifically activate or inactivate only one of 
the receptors within the P2Y receptor family. The P2Y1, P2Y2, and P2Y11 receptors are all coupled to 
the same Gq signaling pathway and can all be activated by adenosine nucleotides. At the P2Y1 
receptor, both isomers of 2-propylthio-ATP-αS, the A-isomer of 2-propylthio-ATP-αB, and 2-propylthio-
ATP induced strong intracellular Ca2+ responses to nucleotide concentrations of 10 µM (Figure 23B). 
However, only for 2-propylthio-ATP a complete concentration-response-curve could be established 
(Figure 24), and the EC50 value was calculated to be 0.04 µM. In the group of nucleotides without a 
dichloromethylene substitution, the B-isomer of 2-propylthio-ATP-αB displayed the lowest intracellular 
Ca2+ response. However, the β,γ-CCl2-substituted nucleotides generally induced lower Ca2+ responses 
to nucleotide concentrations of 10 µM than the nucleotides without a β,γ-CCl2-group. The Rp-isomers 
of 2-propylthio-ATP-αS-β,γ-CCl2 (= B-isomer) and 2-propylthio-ATP-αB-β,γ-CCl2 (= A-isomer) induced 
the lowest responses in 1321N1 astrocytoma cells expressing the P2Y1 receptor. As these nucleotides 
were potent agonists of the P2Y11 receptor, the dichloromethylene group between the β- and γ-
phosphate increased the specificity of the novel nucleotide analogs for the P2Y11 over the P2Y1 
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receptor. Thus, the benefit of the dichloromethylene group here is primarily lies within increased P2Y11 
receptor specificity, rather than an enhanced potency. 
 As described in the introduction (chapter 1.2), the human P2Y2 receptor equally accepts UTP 
and ATP. Of the tested compounds, none but 2-propylthio-ATP was able to induce a notable 
intracellular Ca2+ response at this receptor for a nucleotide concentration of 10 µM (Figure 23C). 
However, 2-propylthio-ATP is only a weak agonist of the P2Y2 receptor since a concentration of 1 µM 
did not result in a detectable Ca2+ response. 
AR-C67085 is an antagonist at the P2Y12 (Ingall et al., 1999) and P2Y13 receptors (Marteau et 
al., 2003). Both receptors are coupled to Gi signaling and therefore mediate the nucleotide-induced 
inhibition of intracellular cAMP signaling. The novel nucleotide derivatives tested here are based on 
the structure of AR-C67085. Therefore, an antagonistic activity at the P2Y12 and P2Y13 receptors 
should be addressed in future studies. 
The novel 2-propylthio-ATP derivatives reveal that the diastereospecificity of the human P2Y11 
receptor affects the induction of cAMP responses. 
 The activation of the P2Y11 receptor triggers the elevation of the intracellular cAMP 
concentration via Gs signaling and subsequent activation of AC. The B-isomers of 
2-propylthio-ATP-αB and 2-propylthio-ATP-αB-β,γ-CCl2 were the most potent analogs for the induction 
of [Ca2+]i elevation in P2Y11 receptor-expressing 1321N1 astrocytoma cells. These analogs triggered 
cAMP accumulation in a concentration-dependent manner (Figure 25). The EC50 value for the 
induction of cAMP signaling by both nucleotides can be estimated to be around 0.1 µM. This is in line 
with their equal potency for the induction of Ca2+ signaling (EC50 = 0.03 µM each). Also in accordance 
with the data from the intracellular Ca2+ measurements is our finding that 2-propylthio-ATP-αB(B) and 
2-propylthio-ATP-αB-β,γ-CCl2(B) were more potent than ATP to trigger cAMP increase (Figure 26). 
The difference in potency for the induction of Ca2+ signaling between the two isomers of 
2-propylthio-ATP-αB was 13-fold. We found a similar difference between these isomers in the ability to 
cause intracellular cAMP accumulation, since the A-isomer of 2-propylthio-ATP-αB induced only a 
weak response at 10 µM. This demonstrates a diastereoselective activation of both the Gq and Gs 
signaling pathways via the human P2Y11 receptor.  
4.2.2 Evaluation of 5-methoxy-substituted derivatives of UDP as P2Y6 receptor 
agonists 
 
5-OMe and Pα substitutions in UDP highly increase the nucleotide potency at the P2Y6 
receptor. 
 Substitutions at position 5 of the nucleobase of uridine nucleotides are well tolerated by the 
P2Y6 receptor since 5-Br-UTP (Communi et al., 1996), 5-Br-UDP, and 5-I-UDP (Nicholas et al., 1996; 
Besada et al., 2006) show agonist activity at this receptor. Here, we investigated the potency of 
5-OMe-substituted derivatives of UDP at the uridine nucleotide-preferring P2Y2, P2Y4, and P2Y6 
receptors expressed in 1321N1 astrocytoma cells to induce intracellular Ca2+ responses (Figure 27). 
Additionally, substitutions of non-bridging oxygen at the phosphate chain, introducing a new chiral 
center, of several mono- and di-nucleotide analogs were analyzed. As discussed above, Pα-
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substituents of non-bridging oxygen have been reported to increase the potency of agonists at the 
P2Y1 and P2Y11 receptors (Major et al., 2004b; Ecke et al., 2006) before.  
 The C5-substition in 5-OMe-UDP makes the compound about 2.6-fold more potent at the 
P2Y6 receptor than the physiological standard agonist UDP (Table 6). The additional introduction of a 
Pα-borano substitution, resulting in 5-OMe-UDP-αB (Figure 32), further increased the nucleotide 
potency by a factor of 11 for the Rp(A)-isomer. Thus, 5-OMe-UDP-αB(A) was about 29-fold more 
potent than UDP, which makes it the most potent P2Y6 receptor agonist known to date. Furthermore, 
the Sp(B)-isomer showed a more than 600-times lower potency than the corresponding A-isomer. As 
a consequence, the B-isomer was 21-fold less potent than UDP. These findings demonstrate a 
previously unknown diastereoselectivity of the human P2Y6 receptor and emphasize the potential to 
enhance agonist potency by exploiting the receptor diastereoselectivity. However, in contrast to the 
highly potent 5-OMe-UDP-αB, 5-OMe-UTP-αB was a poor agonist of the P2Y6 receptor (Ginsburg-
Shmuel et al., 2012). Hence, the 5-OMe and Pα substitutions could not overcome the P2Y6 receptor 
preference for uridine 5’-diphosphates over the respective triphosphates. 
 
 
5-OMe-UDP-αB 
EC50 (P2Y6 receptor) = 0.008 µM (A-isomer) 
 
Figure 32: Structure of 5-OMe-UDP-αB, the most potent of the 5-OMe-substituted derivatives of 
UDP tested at the human P2Y6 receptor expressed in 1321N1 astrocytoma cells. 
 
 Despite the fact that Up3U (uridine 5’-triphosphate 5’’-uridine) was reported to be a potent 
agonist of the P2Y6 receptor (EC50 for the rise of [Ca2+]i = 0.92 µM; Shaver et al., 2005), the 5-OMe-
substituted Up3U derivative (5-OMe-U)-P3-(5-OMe-U) tested here was only a poor agonist of the P2Y6 
receptor (EC50 > 10 µM). The combination of this 5-OMe-substituted di-nucleotide scaffold with a 
boranated α-phosphate, resulting in (5-OMe-U)-P3αB-(5-OMe-U), lead to greatly improved potencies 
for both isomers (EC50 = 0.14 µM and 2.0 µM for the A- and B-isomer, respectively). However, the 
potency of the A-isomer was still about 18-fold lower than that of the corresponding mono-nucleotide 
5-OMe-UDP-αB(A). Apparently, the 5-OMe substitution or potentially the presence of a double 5-OMe 
substitution was detrimental for the potency of the di-nucleotides. Diastereoselectivity of the P2Y6 
receptor for the isomers of (5-OMe-U)-P3αB-(5-OMe-U) was detectable, but was much less 
pronounced than for the isomers of 5-OMe-UDP-αB. The A-isomer of (5-OMe-U)-P3αB-(5-OMe-U) 
was only 14-times more potent than the B-isomer.  
Our data indicate that the position of the borano substitution in uridine di-nucleotides is of 
lesser relevance for the potency at the P2Y6 receptor. The relatively low EC50 value of 0.2 µM for the 
non-chiral (5-OMe-U)-P3βB-(5-OMe-U) almost equaled the EC50 value of 
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(5-OMe-U)-P3αB-(5-OMe-U)(A) of 0.14 µM. Importantly, and similar to the observations made with the 
mono-nucleotides, the borano-substituents at the phosphate chain generally enhanced the potency at 
the human P2Y6 receptor of all 5-OMe-substituted di-nucleotides. 
Boranated phosphates improve P2Y6 receptor selectivity of 5-OMe-UDP analogs. 
 None of the tested 5-OMe-UDP derivatives showed agonist activity at the human P2Y2 
receptor (Figure 30A). At the P2Y4 receptor, 5-OMe-UDP caused a moderate intracellular Ca2+ 
response for a nucleotide concentration of 50 µM, which reached about 50% of the maximal response 
at the P2Y6 receptor (Figure 30B). The additional substitution of a non-bridging oxygen bound to the α-
phosphate by a borano group lead to greatly reduced potency at the P2Y4 receptor of the 5-OMe-UDP 
derivatives, thus influencing nucleotide specificity in favor of the P2Y6 receptor. 
 The insurmountable P2Y6 receptor antagonist MRS2578 (10 µM) reduced the intracellular 
Ca2+ response to 5-OMe-UDP-αB(A), which was given at the same concentration, by almost 80% 
(Figure 29). This result proves that responses to the tested novel nucleotide analogs are indeed driven 
by the P2Y6 receptor. 
4.2.3 Conclusions about structure-activity relationships of the novel P2Y11 and 
P2Y6 receptor agonists 
 
The ability to selectively activate P2Y receptors in a physiological context, i.e. expressed in the 
multi-receptor environment of a human cell or tissue, is a main goal for the development of novel P2Y 
receptor agonists. It can help treating P2Y receptor-associated disorders but also facilitate the 
research of physiological and patho-physiological purinergic processes. For this reason, a large 
number of differently modified nucleotide analogs was evaluated in the past at the known human P2Y 
receptors. Here, novel nucleotide derivatives specifically synthesized for P2Y11 and P2Y6 receptor 
activation were successfully investigated, and promising findings about structure-activity relationships 
were achieved. 
The combination of 2-propylthio and PαB substitutions in ATP greatly enhanced nucleotide 
potency at the P2Y11 receptor, β,γ-CCl2 modification was beneficial for receptor selectivity. 
Here, we identified some of the most potent P2Y11 receptor agonists known. The B-isomers of 
2-propylthio-ATP-αB and 2-propylthio-ATP-αB-β,γ-CCl2 have EC50 values in the nanomolar range 
which are about 87-times lower than the EC50 value of the physiological standard agonist ATP. 
AR-C67085, which is structurally related to the novel nucleotides investigated in the present study, 
was reported to be only 7-fold more potent than ATP for inducing the elevation of IP3 (Communi et al., 
1999). 2-propylthio-ATP-αB(B) and 2-propylthio-ATP-αB-β,γ-CCl2(B) have been shown to be suitable 
for the dual activation of the Gq and Gs signaling pathways linked to the P2Y11 receptor. The Pα 
substitution of 2-propylthio-ATP-derived nucleotides enhanced the nucleotide potency and revealed 
that the P2Y11 receptor has a diastereoselectivity not only for the activation of nucleotide-induced Ca2+ 
signaling but also for cAMP signaling. The β,γ-CCl2 substitution improved the specificity of the 
nucleotide analogs for the P2Y11 receptor over the P2Y1 receptor. This modification is also expected to 
enhance the hydrolytic stability in concert with the Pα-borano substitutions. This makes the Sp(B)-
isomer of 2-propylthio-ATP-αB-β,γ-CCl2 a most interesting candidate for future drug development. 
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The 5-OMe substitution in UDP in addition to a PαB modification greatly enhanced nucleotide 
potency at the P2Y6 receptor.  
 The 5-OMe substitution at the nucleobase of UDP together with the Pα-borano modification 
resulted in the most potent P2Y6 receptor agonist known to date: 5-OMe-UDP-αB(A). Also, the 
experimental results provide the first evidence for a diastereoselectivity of the human P2Y6 receptor. 
Nucleotides are notoriously unstable extracellular compounds, as intercellular purinergic 
signaling often depends on the quick modulation of the respective physiological pathways by 
hydrolytic enzymes. To be suitable drug candidates, however, nucleotides must provide some 
chemical and metabolic stability. It was found by Ginsburg-Shmuel et al. (2012) that a PαB substitution 
in UDP was detrimental to the hydrolytic stability under gastric juice conditions, likely due to the 
vulnerability of the phosphate-borano-bond to acidic hydrolysis. Nevertheless, the half-lifetime of circa 
17 h of the A-isomer of 5-OMe-UDP-αB highly recommends this compound as a drug candidate. The 
resistance against hydrolysis by NPP1 and 3 was significantly enhanced by the PαB substitution of 
5-OMe-UDP-αB(A) when compared with UDP and 5-OMe-UDP. This shows that Pα-borano-
substituted UDP derivatives are poor substrates for NPP1 and 3. In human blood serum, which 
contains multiple hydrolyzing enzymes, a 50% hydrolysis of 5-OMe-UDP-αB(A) was found after 17 h. 
5-OMe-UDP had a half-lifetime of around 12 h, and UDP of only 2.4 h. Thus, the 5-OMe-group 
significantly increased the resistance to hydrolysis in human blood serum and the introduction of a Pα-
borano group even further enhanced the nucleotide stability. 
Furthermore, di-nucleotide derivatives of 5-OMe-UDP might be promising drug candidates, in 
spite of the comparably low potency at the P2Y6 receptor. We base this suggestion on the fact that the 
di-nucleotide scaffold has been reported to provide enhanced chemical and metabolic stability (Yerxa 
et al., 2002; Shaver et al., 2005). 
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5. Zusammenfassung 
 
 Im humanen P2RY11 Gen spielen SNP (Single-Nucleotide-Polymorphism) eine Rolle bei der 
langfristigen Entwicklung verschiedener Krankheiten. Ein SNP in der 3’ UTR steht zum Beispiel mit 
Narkolepsie/Kataplexie, reduzierter Expression des P2Y11 Nukleotid-Rezeptors in Immunzellen und 
einer gesteigerten Anfälligkeit für ATP-induzierten Zelltod in Verbindung. Ein weiterer häufiger SNP im 
kodierenden Bereich dieses Gens führt zur Synthese der Ala-87-Thr (A87T) Variante des P2Y11 
Rezeptors. Der mutierte Rezeptor enthält ein polares Threonin statt des unpolaren Alanin am Ende 
der Transmembranregion-2. Diese Mutation steht mit erhöhtem Herzinfarktrisiko und gesteigerter 
Konzentration von C-reaktivem Protein in Zusammenhang. Die vorliegende Arbeit beschreibt die erste 
funktionelle Charakterisierung des mutierten P2Y11A87T Rezeptors. Im Vergleich mit dem P2Y11 
Wildtyp-Rezeptor konnten wir in HEK293 Zellen eine substantielle Reduktion der Nukleotid-induzierten 
Ca2+ und cAMP Antworten feststellen. Kontrollexperimente ergaben, dass diese Unterschiede nicht 
eine Folge reduzierter Expessionsspiegel des P2Y11A87T Rezeptors sind. Ferner konnten wir in 
HEK293 Zellen keine Nukleotid-induzierte Internalisierung des P2Y11A87T Rezeptors beobachten. 
Trotzdem führte die Langzeit-Stimulation mit ATP zu einer, im Vergleich zum P2Y11 Wildtyp-Rezeptor, 
verstärkten Desensitivierung der intrazellulären Ca2+-Antwort. Die anschließende Resensitivierung der 
Ca2+-Antwort war jedoch deutlich verstärkt. Diese Ergebnisse demonstrieren einen großen Einfluss 
des P2Y11A87T Rezeptors auf zelluläre Langzeit-Antworten.  
Von großer Bedeutung ist unser Befund, dass eine funktionelle Beeinträchtigung des 
P2Y11A87T Rezeptors nur in den Zellen gemessen werden konnte, die gleichzeitig den P2Y1 Rezeptor 
exprimierten. Die Oligomerisierung der P2Y1 und P2Y11 Rezeptoren wurde bereits in einer früheren 
Studie experimentell belegt. Wir schlussfolgern daher, dass die A87T Mutation des P2Y11 Rezeptors 
zu einer Beeinträchtigung der Funktionalität des Rezeptor-Oligomers führt. Zukünftige 
Untersuchungen zur Rolle des humanen P2Y11A87T Rezeptors sollten daher eine Co-Expression des 
P2Y1 Rezeptors berücksichtigen. Das betrifft weitere Untersuchungen über die Verbindung des 
P2Y11A87T Rezeptors zu gesteigertem Herzinfarktrisiko, und auch Studien zu Inflammation und 
Prozessen des Immunsystems mit bekannter P2Y11 Rezeptor Beteiligung. 
 Da die Aktivität von P2Y Rezeptoren bei zahlreichen physiologischen und pathologischen 
Prozessen wichtig ist, stellt die Regulierung der Rezeptoren ein vielversprechendes Ziel für künftige 
therapeutische Ansätze dar. Wir konnten neue chirale Agonisten für humane P2Y Rezeptoren 
identifizieren. Diese Liganden, synthetisiert von Prof. B. Fischer von der Bar-Ilan University in Ramat-
Gan (Israel), können als Basis für weitere pharmakologische Entwicklungen dienen. Sp-2-propylthio-
ATP-αB und Sp-2-propylthio-ATP-αB-β,γ-CCl2 gehören zu den potentesten bekannten P2Y11 
Rezeptor-Agonisten und zeigten eine jeweils 87-fach höhere Potenz, als ATP. Rp-5-OMe-UDP-αB ist 
der potenteste bislang bekannte P2Y6 Rezeptor-Agonist. Er ist 29-fach potenter als UDP und 
offenbarte eine bislang unbekannte Diastereoselektivität des P2Y6 Rezeptors. Diese Ergebnisse 
verdeutlichen, dass die Berücksichtigung der Stereoselektivität von P2Y Rezeptoren für das Design 
stabiler, selektiver und sehr potenter Agonisten von entscheidender Bedeutung ist. 
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6. Abstract 
 
Single-nucleotide polymorphisms (SNP) of the human P2RY11 gene are connected to the 
long-term development of several disorders. A SNP in the 3’ UTR is associated with 
narcolepsy/cataplexy, reduced expression levels of the P2Y11 nucleotide receptor in immune cells, and 
enhanced susceptibility to ATP-induced cell death. A frequent SNP in the coding region of the gene 
leads to the Ala-87-Thr (A87T) variant of the P2Y11 receptor. The resulting mutant P2Y11A87T receptor 
contains a polar threonine residue near the end of the transmembrane region-2 instead of a nonpolar 
alanine. This mutation is associated with increased risk for acute myocardial infarction and elevated 
levels of C-reactive protein. We here present the first functional characterization of the P2Y11A87T 
receptor. Nucleotide-induced Ca2+ and cAMP responses mediated by the P2Y11A87T receptor in 
HEK293 cells were substantially reduced, in comparison with the wildtype P2Y11 receptor. Control 
experiments verified that these reductions were not due to reduced expression levels of the mutated 
P2Y11A87T receptors. We further found that the mutant receptor lacks nucleotide-induced 
internalization in HEK293 cells. Nevertheless, prolonged treatment with ATP leads to increased 
desensitization of the Ca2+ response, compared with the wildtype P2Y11 receptor. This is followed by 
enhanced resensitization of the Ca2+ response. This finding demonstrates an important influence of the 
P2Y11A87T receptor on long-term cellular responses. 
Importantly, we detected functional impairments of the mutant P2Y11A87T receptor only in 
cells, which co-express the P2Y11A87T receptor together with the P2Y1 receptor. Oligomerization of 
P2Y1-P2Y11 receptors has been shown before by several lines of evidence in a previous study. We 
thus conclude that the A87T amino acid shift in the P2Y11 receptor has a detrimental effect on the 
functionality of the oligomer. Consequently, future research on the contribution of the A87T mutation of 
the human P2Y11 receptor to cellular dysfunctions and pathological processes should consider P2Y1 
receptor co-expression in cells. This includes studies of the contribution of the P2Y11A87T receptor to 
acute myocardial infarction but also other inflammatory and immune system-related processes with 
known P2Y11 receptor contribution. 
Since P2Y receptor activity is connected to many physiological and pathological processes, 
the modulation of P2Y receptor signaling is a promising goal for future therapeutic approaches. We 
identified novel chiral agonists of human P2Y receptors. The ligands, synthesized by Prof. B. Fischer 
from the Bar-Ilan University, Ramat-Gan, Israel, are a basis for further drug development. We 
identified Sp-2-propylthio-ATP-αB and Sp-2-propylthio-ATP-αB-β,γ-CCl2 as the most potent known 
agonists of the P2Y11 receptor with 87-fold higher potency than ATP. We found that 
Rp-5-OMe-UDP-αB is the most potent P2Y6 receptor agonist known so far. It is 29-fold more potent 
than UDP and revealed a previously unknown diastereoselectivity of the P2Y6 receptor. Thus, 
exploiting the stereoselectivity of P2Y receptors is vital for the development of stable, selective, and 
very potent agonists. 
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7. Abbreviations 
 
# 
[Ca2+]i: intracellular calcium concentration 
2-Cl-ATP: 2-chloro-adenosine 5’-triphosphate 
2-Cl-ATP-αB: 2-chloro-adenosine 5’-triphosphate- 
α-borano 
2-MeS-ADP: 2-methlythio-adenosine 5’-diphosphate 
2-MeS-ATP: 2-methylthio-adenosine 5’-triphosphate  
2-MeS-ATP-αB: 2-methylthio-adenosine 5’-
triphosphate-α-borano 
5-Br-UTP: 5-bromo-uridine 5’-triphosphate 
5-I-UDP: (5-iodo-uridine 5’-diphosphate) 
7TMR: seven-transmembrane receptor 
A 
ABC: ATP-binding cassette 
AC: adenylyl cyclase 
ADP: adenosine 5’-diphosphate  
AMP: adenosine 5’-monophosphate 
AMI: acute myocardial infarction 
ATP: adenosine 5’-triphosphate 
ATP-αB: adenosine 5’-triphosphate-α-borano 
ATP-βS: adenosine 5’-triphosphate-β-thio 
ATP-γS: adenosine 5’-triphosphate-γ-thio 
Ap3A: adenosine 5’-triphospho 5’’-adenosine, 
diadenosine triphosphate 
Ap4A: adenosine 5’-tetraphospho 5’’-adenosine, 
diadenosine tetraphosphate 
Ap5A: adenosine 5’-pentaphospho 5’’-adenosine, 
diadenosine pentaphosphate 
Ap6A: adenosine 5’-hexaphospho 5’’-adenosine, 
diadenosine hexaphosphate 
Ap4U: adenosine 5’-tetraphosphate 5’’-uridine 
AR-C67085: 2-propylthio-ATP-β,γ-dichloromethylene 
B 
BzATP: 2'(3')-O-(4-Benzoylbenzoyl)adenosine 5'-
triphosphate 
C 
cAMP: 3’-5’-cyclic adenosine monophosphate 
CDP: cytidine 5'-diphosphate 
cGMP: 3’-5’-cyclic guanosine monophosphate 
CFTR: cystic fibrosis transmembrane conductance 
regulator 
CTP: cytidine 5'-triphosphate 
CysLT1R: cysteinyl leukotriene receptor 1 
D  
Dabco: 1,4-Diazabicyclo[2.2.2]octane 
dATP: 2'-deoxyadenosine 5'-triphosphate 
DC: dendritic cell 
E 
E-NTPDase: ecto-nucleoside triphosphate 
diphosphohydrolase 
E-NPP: ecto-nucleotide 
pyrophosphatase/phosphodiesterase  
Ecto-NDPK: ecto-nucleoside diphosphokinase 
EL: extracellular loop 
Erk: extracellular signal-related protein kinase 
F 
FAD: flavin adenine dinucleotide  
FCS: fetal calf serum 
FRET: fluorescence resonance energy transfer 
G 
GC: guanylyl cyclase 
GPCR: G protein-coupled receptor 
GRK: G protein-coupled receptor kinase 
GST: glutatione S-transferase 
GTP: guanosine 5’-triphosphate 
H  
HNP: human neutrophil peptide 
I  
IBMX: isobutyl-methyl-xanthine 
IL: interleukin  
ITP: inosine 5’-triphosphate 
IP3: inositol-1,4,5-trisphosphate 
M 
MAPK: mitogen-activated protein kinase 
mBMMC: mouse bone marrow-derived mast cell  
MRS2179: N6-methyl-2’-deoxyadenosine 3’,5’ 
diphosphate 
MRS2578: 1,4-di-[(3-isothio-cyanato phenyl)-
thioureido]butane 
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MRS2957: N4-methoxy-cytidine 5’-triphosphate 5’’-
uridine 
N 
NAD: nicotinamide adenine dinucleotide 
NADP: nicotinamide adenine dinucleotide phosphate 
NO: nitric oxide 
P 
PKA: protein kinase A / cAMP-dependent protein 
kinase 
PKC: protein kinase C 
PLC: protein lipase C 
Pi: orthophosphate 
PPi: pyrophosphate 
R 
RT: room temperature  
S 
siRNA: small interfering ribonucleic acid 
SNP: single-nucleotide polymorphism  
T 
TNF-α: tumor necrosis factor-α 
TTP: thymidine 5’-triphosphate 
U 
Up3U: uridine 5’-triphospho 5’’-uridine, diuridine 
triphosphate 
UTP: uridine 5’-triphosphate 
UTP-βS: uridine 5’-triphosphate-β-thio 
UDP: uridine 5’-diphosphate 
V 
VNUT: vesicular nucleotide transporter SLC17A9
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